<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03150056</url>
  </required_header>
  <id_info>
    <org_study_id>204697</org_study_id>
    <secondary_id>2016-003416-13</secondary_id>
    <nct_id>NCT03150056</nct_id>
  </id_info>
  <brief_title>Dose Escalation and Dose Expansion Study of GSK525762 in Combination With Androgen Deprivation Therapy in Participants With Castrate-resistant Prostate Cancer</brief_title>
  <official_title>A Phase IB Open-label, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK525762 in Combination With Androgen Deprivation Therapy and Other Agents in Subjects With Castrate-resistant Prostate Cancer (CRPC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to evaluate the combination of GSK525762 with other agents that have been&#xD;
      shown to be effective in the treatment of CRPC or metastatic (m)CRPC. This study is designed&#xD;
      to determine the maximum tolerated dose (MTD) and recommended Phase II dose (RP2D) based on&#xD;
      safety, tolerability, pharmacokinetic, and efficacy profiles of GSK525762 in combination with&#xD;
      either abiraterone (Arm A) or enzalutamide (Arm B).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 18, 2017</start_date>
  <completion_date type="Actual">June 22, 2021</completion_date>
  <primary_completion_date type="Actual">July 31, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This will be a two-arm, open-label dose escalation and dose expansion cohort study.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Any Adverse Events (AEs) and Serious Adverse Events (SAEs)</measure>
    <time_frame>Up to 21.3 months</time_frame>
    <description>An AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose: results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, any other situation according to medical or scientific judgement, or is associated with liver injury and impaired liver function.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With AEs Leading to Any Dose Reduction or Delays</measure>
    <time_frame>Up to 21.3 months</time_frame>
    <description>An AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Number of participants with AEs leading to any dose reduction or delays have been presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Who Withdrew Due to Toxicity and Changes in Safety Assessment</measure>
    <time_frame>Up to 21.3 months</time_frame>
    <description>Number of participants who withdrew due to toxicity and changes in safety assessment including laboratory parameters and vital signs have been presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With &gt;=50 Percent (%) Decrease in Prostate-specific Antigen From Baseline (PSA50)</measure>
    <time_frame>Up to 21.3 months</time_frame>
    <description>PSA50 response rate is defined as percentage of participants with a decrease of &gt;=50% in the PSA concentration from the Baseline PSA value determined at least 12 weeks after start of treatment and confirmed &gt;=4 weeks later by an additional PSA evaluation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) of GSK525762 and Its Active Metabolites GSK3529246</measure>
    <time_frame>Day 1: Pre-dose, 30 minutes, 1, 3, 6 to 12, 24 hours post-dose on Weeks 1 and 3</time_frame>
    <description>Blood samples were collected at indicated time points for pharmacokinetic (PK) analysis of GSK525762 and GSK3529246 (metabolite of GSK525762). PK parameters were calculated using standard non-compartmental analysis. PK Population consisted of all participants from the All Treated Safety Population for whom a PK sample was obtained and analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Cmax (Tmax) of GSK525762 and Its Active Metabolites GSK3529246</measure>
    <time_frame>Day 1: Pre-dose, 30 minutes, 1, 3, 6 to 12, 24 hours post-dose on Weeks 1 and 3</time_frame>
    <description>Blood samples were collected at indicated time points for PK analysis of GSK525762 and GSK3529246 (metabolite of GSK525762). PK parameters were calculated using standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration-time Curve From Time Zero to the End of the Dosing Interval (AUC[0-tau]) of GSK525762 and Its Active Metabolites GSK3529246</measure>
    <time_frame>Day 1: Pre-dose, 30 minutes, 1, 3, 6 to 12, 24 hours post-dose on Weeks 1 and 3</time_frame>
    <description>Blood samples were collected at indicated time points for PK analysis of GSK525762 and GSK3529246 (metabolite of GSK525762). PK parameters were calculated using standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough Concentration (Ctrough) of GSK525762 and Its Active Metabolites GSK3529246</measure>
    <time_frame>Day 1: Pre-dose, 30 minutes, 1, 3, 6 to 12, 24 hours post-dose on Weeks 1 and 3</time_frame>
    <description>Blood samples were collected at indicated time points for PK analysis of GSK525762 and GSK3529246 (metabolite of GSK525762). PK parameters were calculated using standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of Abiraterone</measure>
    <time_frame>Day 1: Pre-dose, 30 minutes, 1, 3, 6 to 12, 24 hours post-dose on Weeks 1 and 3</time_frame>
    <description>Blood samples were collected at indicated time points for PK analysis of abiraterone. PK parameters were calculated using standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of Abiraterone</measure>
    <time_frame>Day 1: Pre-dose, 30 minutes, 1, 3, 6 to 12, 24 hours post-dose on Weeks 1 and 3</time_frame>
    <description>Blood samples were collected at indicated time points for PK analysis of abiraterone. PK parameters were calculated using standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC(0-tau) of Abiraterone</measure>
    <time_frame>Day 1: Pre-dose, 30 minutes, 1, 3, 6 to 12, 24 hours post-dose on Weeks 1 and 3</time_frame>
    <description>Blood samples were collected at indicated time points for PK analysis of abiraterone. PK parameters were calculated using standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ctrough of Abiraterone</measure>
    <time_frame>Day 1: Pre-dose, 30 minutes, 1, 3, 6 to 12, 24 hours post-dose on Weeks 1 and 3</time_frame>
    <description>Blood samples were collected at indicated time points for PK analysis of abiraterone. PK parameters were calculated using standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of Enzalutamide</measure>
    <time_frame>Day 1: Pre-dose on Weeks 1, 3, 5, 9, 17 and 25</time_frame>
    <description>Blood samples were collected at indicated time points for PK analysis of enzalutamide. PK parameters were calculated using standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of Enzalutamide</measure>
    <time_frame>Day 1: Pre-dose on Weeks 1, 3, 5, 9, 17 and 25</time_frame>
    <description>Blood samples were collected at indicated time points for PK analysis of enzalutamide. PK parameters were calculated using standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC(0-tau) of Enzalutamide</measure>
    <time_frame>Day 1: Pre-dose on Weeks 1, 3, 5, 9, 17 and 25</time_frame>
    <description>Blood samples were collected at indicated time points for PK analysis of enzalutamide. PK parameters were calculated using standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ctrough of Enzalutamide</measure>
    <time_frame>Day 1: Pre-dose on Weeks 1, 3, 5, 9, 17 and 25</time_frame>
    <description>Blood samples were collected at indicated time points for PK analysis of enzalutamide. PK parameters were calculated using standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate at Week 24</measure>
    <time_frame>Week 24</time_frame>
    <description>Disease control rate (DCR) is defined as the percentage of participants with &gt;=1 post-Baseline disease assessment who showed either a confirmed complete response (CR), partial response (PR) or stable disease (SD) observed at &gt;=24 weeks per prostate cancer working group 3 (PCWG3)-modified Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1; where CR: disappearance of all target lesions. Any pathological lymph nodes must be &lt;10 millimeter in the short axis; PR: At least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the Baseline sum of the diameters; SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive diseases. Confidence interval (CI) was computed using exact two sided 95% CI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite Response Rate</measure>
    <time_frame>Up to 21.3 months</time_frame>
    <description>Composite response rate was defined as the percentage of participants with one of the following: a) Response based on PCWG3-modified RECIST version 1.1, b) PSA decrease of &gt;=50% from Baseline at Week 12 and thereafter, or c) Circulating Tumor-cell Count Conversion from unfavorable (&gt;=5/7.5 milliliter [mL]) at Baseline to favorable (&lt;5/7.5 mL) confirmed by a second assessment at least 4 weeks later. If a participant met at least one of the above requirements, then that participant was considered a composite responder. CI was computed using exact two sided 95% CI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate</measure>
    <time_frame>Up to 21.3 months</time_frame>
    <description>Objective response rate (ORR) is defined as the percentage of participants with a confirmed CR or PR at any time as per PCWG3-modified RECIST version 1.1; where CR: Disappearance of all target lesions. Any pathological lymph nodes must be &lt;10 millimeter (mm) in the short axis and PR: At least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the Baseline sum of the diameters.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Circulating Tumor Cells (CTC) Response Rate</measure>
    <time_frame>Up to 21.3 months</time_frame>
    <description>CTC response rate is defined as the percentage of participants with a CTC conversion to &lt;5/7.5 mL blood at nadir (confirmed by a second consecutive value obtained four or more weeks later) for participants with unfavourable CTC (&gt;=5/7.5 mL) at Baseline. CI was computed using exact two sided 95% CI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prostate-specific Antigen (PSA) Response Rate at Week 4</measure>
    <time_frame>Week 4</time_frame>
    <description>PSA Response Rate is defined as percentage of participants achieving &gt;=30% decrease from Baseline PSA after 4 weeks of study treatment. The CI was calculated using exact two sided 95% CI for the percentage of participants with Baseline PSA values who show &gt;=30% reduction in PSA at &gt;=4 weeks post-Baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Disease Progression</measure>
    <time_frame>Up to 21.3 months</time_frame>
    <description>Time to disease progression is defined as the time from date of first dose of study treatment to date of disease progression defined as one or more of the following criteria: 1. Radiographic progression by PCWG3-modified RECIST version 1.1 for participants with measurable disease, 2. Bone progression on bone scan according to the PCGW3 criteria, 3. PSA progression according to the PCWG3 criteria accompanied by any one of the following: investigator-defined clinical progression or either of the above RECIST version 1.1 radiographic progression or bone progression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiographic Progression-free Survival (rPFS)</measure>
    <time_frame>Up to 21.3 montths</time_frame>
    <description>rPFS is defined as the time from study treatment start until the first date of either disease progression or death due to any cause. The date of disease progression is defined as the earliest date of disease progression as assessed by the investigator using PCWG3-modified RECIST, version 1.1 or progression on bone scan. Progressive disease is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as a reference, the smallest sum of diameters recorded since the treatment started.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Worst-Case Post Baseline Eastern Cooperative Oncology Group (ECOG) Performance Status</measure>
    <time_frame>Up to 21.3 months</time_frame>
    <description>Performance status assessments were based on 6-point ECOG scale (from 0 to 5), where 0=fully active, able to carry on all pre-disease performance without restriction; 1=restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature (e.g., light house work, office work); 2=ambulatory and capable of all self-care but unable to carry out any work activities, up and about more than 50% of waking hours; 3=capable of only limited self-care, confined to bed or chair more than 50% of waking hours; 4=completely disabled, cannot carry on any self-care, totally confined to bed or chair; and 5=dead. Data for worst case post-Baseline is presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC QLQ-C30): Global Health Status (GHS)</measure>
    <time_frame>Baseline (up to Week 1 Day 1, pre-dose) and at Weeks 1, 2, 3, 4, 5, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, 61 on Day 1</time_frame>
    <description>EORTC QLQ-C30 includes 30-items with single and multi-item scales. These included 5 functional scales (physical functioning, role functioning, cognitive functioning, emotional functioning and social functioning, 3 symptom scales (fatigue, pain and nausea/vomiting), a GHS/ Quality-of-Life (QoL) scale, and six single items (constipation, diarrhea, insomnia, dyspnea, appetite loss and financial difficulties). Response options for GHS/QoL range from 1 to 4, where 1=not at all and 4=very much. Scores were averaged and transformed to a 0 to 100 scale, with higher scores representing a high QoL. Baseline is defined as the latest non-missing assessment time-point prior to the first study treatment dose. Change from Baseline was calculated as post-Baseline visit value minus Baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Brief Pain Inventory - Short Form (BPI-SF): Pain Intensity- Pain at Worst in Last 24 Hours</measure>
    <time_frame>Baseline (up to pre-dose on Week 1 Day 1) and at Weeks 2, 3, 4, 5, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, 61, 73, 85, 97 on Day 1</time_frame>
    <description>BPI-SF is 9-item self-administered questionnaire. Pain intensity score was calculated from the four items (items 3, 4, 5 and 6) for worst pain, least pain, average pain and current pain. Worst pain in last 24 hours was rated from 0 (no pain) to 10 (pain as bad as you can imagine). Baseline is defined as the latest non-missing assessment time-point prior to the first study treatment dose (latest up to Week 1 Day 1). Change from Baseline was calculated as post-Baseline visit value minus Baseline value.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">73</enrollment>
  <condition>Solid Tumours</condition>
  <arm_group>
    <arm_group_label>GSK525762 + Abiraterone (+ Prednisone) (Arm A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>GSK525762 + Enzalutamide (Arm B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK525762</intervention_name>
    <description>GSK525762 will be administered.</description>
    <arm_group_label>GSK525762 + Abiraterone (+ Prednisone) (Arm A)</arm_group_label>
    <arm_group_label>GSK525762 + Enzalutamide (Arm B)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abiraterone</intervention_name>
    <description>Abiraterone will be administered.</description>
    <arm_group_label>GSK525762 + Abiraterone (+ Prednisone) (Arm A)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enzalutamide</intervention_name>
    <description>Enzalutamide will be administered.</description>
    <arm_group_label>GSK525762 + Enzalutamide (Arm B)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>Prednisone will be administered as a concomitant medication in combination with abiraterone</description>
    <arm_group_label>GSK525762 + Abiraterone (+ Prednisone) (Arm A)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent provided.&#xD;
&#xD;
          -  Males &gt;=18 years of age (at the time written consent is obtained for screening).&#xD;
&#xD;
          -  Histologically confirmed adenocarcinoma of the prostate: screening and on-treatment&#xD;
             biopsy is mandatory. If adequate number of paired biopsy samples are collected (&gt;=20&#xD;
             paired samples for each dose level in each Arm, unless an Arm is closed early), then&#xD;
             further biopsy sampling will be considered based on available data; screening biopsy&#xD;
             can be waived if participant had a recent biopsy after failure of the most recent&#xD;
             therapy (within 30 days) and the biopsy sample is secured to be sent as screening&#xD;
             biopsy for this study.&#xD;
&#xD;
          -  Surgically or medically castrated, with testosterone levels of less than or equal to&#xD;
             (&lt;=)50 nanograms per deciliter (ng/dL) (&lt;2.0 nanometer [nM]). If the participant is&#xD;
             being treated with luteinizing hormone-releasing hormone (LHRH) agonists/antagonists&#xD;
             (participant who have not undergone orchiectomy) this therapy must have been initiated&#xD;
             at least 4 weeks prior to Week 1 Day 1 and must be continued throughout the study.&#xD;
&#xD;
          -  Participants must have failed prior therapy with abiraterone, enzalutamide, or both:&#xD;
&#xD;
               1. Has completed at least 12 weeks of prior continuous therapy with abiraterone or&#xD;
                  enzalutamide in any prior line.&#xD;
&#xD;
               2. Lead-in dosing period for enzalutamide only will be required under the following&#xD;
                  circumstance:&#xD;
&#xD;
             (i) If the participant has enzalutamide discontinuation for &gt;7 days prior to dosing&#xD;
             start with GSK525762 plus enzalutamide on trial, then a enzalutamide only lead-in&#xD;
             dosing of 28 days is required.&#xD;
&#xD;
        (ii) If the participant has enzalutamide discontinuation for &lt;=7 days prior to dosing start&#xD;
        with GSK525762 plus enzalutamide on trial, then an enzalutamide only lead-in dosing of 14&#xD;
        days is required.&#xD;
&#xD;
        (iii) If the participant is on continuous dosing with enzalutamide prior to dosing start&#xD;
        with GSK525762 plus enzalutamide on trial, then participant can start on combined dosing at&#xD;
        end of screening period.&#xD;
&#xD;
        (c) Lead-in dosing period for abiraterone only will be required: if the participant has&#xD;
        abiraterone discontinuation for more than 3 days prior to dosing start with GSK525762 plus&#xD;
        abiraterone on trial, then abiraterone only lead-in dosing of 7 days is required.&#xD;
&#xD;
          -  One to two line(s) of prior taxane-based chemotherapy allowed. If docetaxel&#xD;
             chemotherapy is used more than once, this will be considered as one regimen.&#xD;
             Participants who have not received prior chemotherapy in any setting will qualify for&#xD;
             study if they are ineligible for or refuse chemotherapy.&#xD;
&#xD;
          -  Documented prostate cancer progression as assessed by the investigator with one of the&#xD;
             following:&#xD;
&#xD;
               1. PSA progression defined by a minimum of 3 rising PSA levels with an interval of&#xD;
                  &gt;=1 week between each determination. The PSA value at screening must be &gt;=5&#xD;
                  microgram (Âµg)/Liter (L) (5 ng/mL) if PSA is the only indication of progression;&#xD;
                  participants on systemic glucocorticoids for control of symptoms must have&#xD;
                  documented PSA progression by PCWG3 while on systemic glucocorticoids prior to&#xD;
                  commencing Week 1 Day 1 treatment.&#xD;
&#xD;
               2. Radiographic progression of soft tissue disease by PCWG3-modified RECIST 1.1&#xD;
                  criteria or bone metastasis with 2 or more documented new bone lesions on a bone&#xD;
                  scan with or without PSA progression.&#xD;
&#xD;
          -  ECOG performance status of 0 or 1.&#xD;
&#xD;
          -  Life expectancy &gt;12 weeks.&#xD;
&#xD;
          -  Able to swallow and retain orally administered medication.&#xD;
&#xD;
          -  Must have adequate organ function.&#xD;
&#xD;
          -  Male participants are eligible to participate if they agree to use contraceptive&#xD;
             methods.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Surgery or local prostatic intervention (excluding a prostatic biopsy) less than 28&#xD;
             days of Week 1 Day 1.&#xD;
&#xD;
          -  Participants with neuroendocrine and/or small cell CRPC.&#xD;
&#xD;
          -  Recent prior therapy, defined as:&#xD;
&#xD;
               1. Any investigational or approved non-biologic anti-cancer drug within 14 days&#xD;
                  prior to the first dose of GSK525762 and abiraterone/enzalutamide.&#xD;
&#xD;
               2. Any nitrosoureas or mitomycin C within 42 days prior to the first dose of&#xD;
                  GSK525762 and abiraterone/enzalutamide.&#xD;
&#xD;
               3. Any anti-cancer biologic agents within five half-lives prior to the first dose of&#xD;
                  GSK525762 and abiraterone/enzalutamide.&#xD;
&#xD;
               4. If the participant received radiotherapy &lt;90 days prior to study treatment, the&#xD;
                  irradiated lesion cannot be the only lesion used for evaluating response.&#xD;
&#xD;
               5. Any major surgery within 28 days prior to the first dose of GSK525762 and&#xD;
                  abiraterone/enzalutamide.&#xD;
&#xD;
          -  Evidence of severe or uncontrolled systemic diseases (e.g., unstable or uncompensated&#xD;
             respiratory, hepatic, renal, cardiac disease, or clinically significant bleeding&#xD;
             episodes). Any serious and/or unstable pre-existing medical (aside from malignancy),&#xD;
             psychiatric disorder, or other conditions that could interfere with participant's&#xD;
             safety, obtaining informed consent or compliance to the study procedures, in the&#xD;
             opinion of the Investigator; systolic blood pressure higher than 150 millimeter of&#xD;
             mercury (mmHg) or diastolic blood pressure higher than 90 mmHg found on 2 separate&#xD;
             occasions separated by 1 week, despite adequate therapy, will be defined as&#xD;
             uncontrolled hypertension; uncontrolled diabetes mellitus (despite therapeutic,&#xD;
             compliance intervention) as defined by a hemoglobin A1c (HbA1c) level more than 8%&#xD;
             and/or occurrence of more than 2 episodes of ketoacidosis in the 12 months prior to&#xD;
             the first dose of study drug.&#xD;
&#xD;
          -  Cardiac abnormalities as evidenced by any of the following:&#xD;
&#xD;
               1. Baseline QT interval corrected for heart rate by Fridericia's formula (QTcF)&#xD;
                  interval &gt;=480 milliseconds (msec).&#xD;
&#xD;
               2. Clinically significant conduction abnormalities or arrhythmias, such as&#xD;
                  participants with second degree (Type II) or third degree atrio-ventricular&#xD;
                  block.&#xD;
&#xD;
               3. History or evidence of current &gt;=Class II congestive heart failure as defined by&#xD;
                  New York Heart Association (NYHA).&#xD;
&#xD;
               4. History of acute coronary syndromes (including unstable angina and myocardial&#xD;
                  infarction), coronary angioplasty, or stenting within the past 3 months.&#xD;
                  Participants with a history of stent placement requiring ongoing anti-coagulant&#xD;
                  therapy (e.g., clopidogrel, prasugrel) will not be permitted to enroll.&#xD;
&#xD;
               5. Known cardiac metastasis.&#xD;
&#xD;
          -  Participants with history of known bleeding disorder(s) or history of clinically&#xD;
             significant hemorrhage (e.g., gastrointestinal, neurologic), within the past 6 months.&#xD;
&#xD;
          -  Therapeutic-dose anticoagulation (e.g., warfarin, low-molecular weight heparin [LMWH],&#xD;
             or novel oral anticoagulants) must be discontinued and coagulation parameters must be&#xD;
             normalized prior to the first dose of GSK525762 and abiraterone/enzalutimide.&#xD;
             Prophylactic anticoagulation, with low doses (per standard practice) of agents such as&#xD;
             LMWH, direct thrombin inhibitors, or factor Xa inhibitors is permitted.&#xD;
&#xD;
          -  Concurrent use of high dose aspirin (doses up to 81 milligrams (mg) oral dose daily&#xD;
             allowed, or 100 mg, as per country standards) and non-steroidal anti-inflammatory&#xD;
             drugs (NSAIDS), except for where NSAIDs provide documented benefit over other&#xD;
             analgesics, and then to be used with caution including concomitant use of proton pump&#xD;
             inhibitors).&#xD;
&#xD;
          -  Any acute toxicities due to prior chemotherapy and / or radiotherapy that have not&#xD;
             resolved to a National Cancer Institute-Common Terminology Criteria for Adverse Events&#xD;
             (NCI-CTCAE) version 4.0 grade &lt;=1 with the exception of chemotherapy induced alopecia&#xD;
             and grade 2 peripheral neuropathy.&#xD;
&#xD;
          -  The participant has an active second malignancy other than curatively resected basal&#xD;
             cell or squamous cell carcinoma of the skin, in situ carcinoma of the bladder, or&#xD;
             other cancers for which they are treated with curative intent with no active disease&#xD;
             in the 3 years prior to enrollment.&#xD;
&#xD;
          -  Participants with known symptomatic brain metastasis are not suitable for enrolment.&#xD;
             Participants with asymptomatic, stable, treated brain metastases are eligible for&#xD;
             study entry.&#xD;
&#xD;
          -  History of seizure within 6 months of study treatment initiation or any condition that&#xD;
             may predispose participant to seizure (e.g., prior cortical stroke or significant&#xD;
             brain trauma) or who are currently being treated with cytochrome P450 enzyme inducing&#xD;
             anti-epileptic drugs for seizures (use of anti-epileptic drugs to control pain is&#xD;
             allowed in participants not suffering from seizures unless drug is excluded due to&#xD;
             Cytochrome (CY)P3A4 induction - phenytoin, carbamazepine, phenobarbital).&#xD;
&#xD;
          -  History of loss of consciousness or transient ischemic attack within 12 months prior&#xD;
             to enrollment.&#xD;
&#xD;
          -  Participants with symptomatic or impending cord compression unless appropriately&#xD;
             treated beforehand and clinically stable and asymptomatic.&#xD;
&#xD;
          -  Current use of a prohibited medication or planned use of any forbidden medications&#xD;
             during treatment with GSK525762 and abiraterone/enzalutamide. This includes&#xD;
             medications that are potent inducers or inhibitors of CYP3A4 enzymes or strong&#xD;
             inhibitors of CYP2C8.&#xD;
&#xD;
          -  Participants with gastrointestinal disorders likely to interfere with absorption of&#xD;
             the study medication.&#xD;
&#xD;
          -  Participants with known bleeding diathesis.&#xD;
&#xD;
          -  Current active liver or biliary disease (with the exception of Gilbert's syndrome or&#xD;
             asymptomatic gallstones, liver metastases or otherwise stable chronic liver disease&#xD;
             per investigator assessment).&#xD;
&#xD;
          -  Initiating bisphosphonate or denosumab therapy or adjusting dose/regimen within 3&#xD;
             months prior to Week 1 Day 1. Participants on a stable bisphosphonate or denosumab&#xD;
             therapy are eligible and may continue.&#xD;
&#xD;
          -  Any serious known immediate or delayed hypersensitivity reaction to GSK525762 or&#xD;
             idiosyncrasy to drugs chemically related to the investigational drugs. Additionally,&#xD;
             any known hypersensitivity to either enzalutamide, abiraterone or any excipients would&#xD;
             be excluded.&#xD;
&#xD;
          -  Known history of human immunodeficiency virus (HIV).&#xD;
&#xD;
          -  Presence of hepatitis B surface antigen (HBsAg) or positive hepatitis C antibody test&#xD;
             result at screening.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Towson</city>
        <state>Maryland</state>
        <zip>21204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Clayton</city>
        <state>Victoria</state>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <zip>8036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Malaga</city>
        <zip>3075EA</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sabadell (Barcelona)</city>
        <zip>08208</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Santander</city>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sutton</city>
        <state>London</state>
        <zip>SM2 5NG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Glasgow</city>
        <zip>G12 OYN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Canada</country>
    <country>France</country>
  </removed_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>May 9, 2017</study_first_submitted>
  <study_first_submitted_qc>May 9, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 11, 2017</study_first_posted>
  <results_first_submitted>July 29, 2021</results_first_submitted>
  <results_first_submitted_qc>July 29, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">August 26, 2021</results_first_posted>
  <last_update_submitted>October 6, 2021</last_update_submitted>
  <last_update_submitted_qc>October 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Abiraterone</keyword>
  <keyword>Castrate-resistant prostate cancer</keyword>
  <keyword>Androgen receptor targeted therapy</keyword>
  <keyword>RP2D</keyword>
  <keyword>Enzalutamide</keyword>
  <keyword>GSK525762</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>IPD for this study will be made available via the Clinical Study Data Request site.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.</ipd_time_frame>
    <ipd_access_criteria>Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted when justified, for up to another 12 months.</ipd_access_criteria>
    <ipd_url>http://clinicalstudydatarequest.com</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>May 6, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/56/NCT03150056/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 22, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/56/NCT03150056/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This was an open-label, dose escalation and expansion study to investigate safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK525762 in combination with abiraterone or enzalutamide in participants with castrate resistant prostate cancer (CRPC).</recruitment_details>
      <pre_assignment_details>This study has been terminated due to meeting protocol defined futility based on an interim analysis. One participant has chosen to continue to receive study drug. The study will conclude when the last participant has completed/discontinued study treatment and completed the end of treatment visit. The results presented are based on the primary analysis at approximately up to 3 years. Data collection is still on-going and additional results will be provided after study completion.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>GSK525762 60 mg+Abiraterone 1000 mg</title>
          <description>Participants received once daily oral dose of GSK525762 60 milligram (mg) in combination with abiraterone 1000 mg up to maximum of 21.3 months. Participants received prednisone 5 mg orally twice daily as per abiraterone label.</description>
        </group>
        <group group_id="P2">
          <title>GSK525762 60 mg Alternate+Abiraterone 1000 mg</title>
          <description>Participants received an alternate dosing schedule- once daily GSK525762 60 mg + abiraterone 1000 mg tablets via the oral route for 2 weeks followed by 1 week off-treatment up to maximum of 21.3 months. Participants received prednisone 5 mg orally twice daily as per abiraterone label.</description>
        </group>
        <group group_id="P3">
          <title>GSK525762 40 mg+Abiraterone 1000 mg</title>
          <description>Participants received once daily oral dose of GSK525762 40 mg in combination with abiraterone 1000 mg up to maximum of 21.3 months. Participants received prednisone 5 mg orally twice daily as per abiraterone label.</description>
        </group>
        <group group_id="P4">
          <title>GSK525762 80 mg+Enzalutamide 160 mg</title>
          <description>Participants received once daily oral dose of GSK525762 80 mg in combination with enzalutamide 160 mg up to maximum of 21.3 months.</description>
        </group>
        <group group_id="P5">
          <title>GSK525762 60 mg+Enzalutamide 160 mg</title>
          <description>Participants received once daily oral dose of GSK525762 60 mg in combination with enzalutamide 160 mg up to maximum of 21.3 months.</description>
        </group>
        <group group_id="P6">
          <title>GSK525762 60 mg Alternate+Enzalutamide 160 mg</title>
          <description>Participants received an alternate dosing schedule- once daily GSK525762 60 mg + enzalutamide 160 mg tablets via the oral route for 2 weeks followed by 1 week off-treatment up to maximum of 21.3 months.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="10"/>
                <participants group_id="P5" count="22"/>
                <participants group_id="P6" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="9"/>
                <participants group_id="P5" count="16"/>
                <participants group_id="P6" count="18"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Study terminated by Sponsor</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="8"/>
                <participants group_id="P6" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Ongoing in the study</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>GSK525762 60 mg+Abiraterone 1000 mg</title>
          <description>Participants received once daily oral dose of GSK525762 60 milligram (mg) in combination with abiraterone 1000 mg up to maximum of 21.3 months. Participants received prednisone 5 mg orally twice daily as per abiraterone label.</description>
        </group>
        <group group_id="B2">
          <title>GSK525762 60 mg Alternate+Abiraterone 1000 mg</title>
          <description>Participants received an alternate dosing schedule- once daily GSK525762 60 mg + abiraterone 1000 mg tablets via the oral route for 2 weeks followed by 1 week off-treatment up to maximum of 21.3 months. Participants received prednisone 5 mg orally twice daily as per abiraterone label.</description>
        </group>
        <group group_id="B3">
          <title>GSK525762 40 mg+Abiraterone 1000 mg</title>
          <description>Participants received once daily oral dose of GSK525762 40 mg in combination with abiraterone 1000 mg up to maximum of 21.3 months. Participants received prednisone 5 mg orally twice daily as per abiraterone label.</description>
        </group>
        <group group_id="B4">
          <title>GSK525762 80 mg+Enzalutamide 160 mg</title>
          <description>Participants received once daily oral dose of GSK525762 80 mg in combination with enzalutamide 160 mg up to maximum of 21.3 months.</description>
        </group>
        <group group_id="B5">
          <title>GSK525762 60 mg+Enzalutamide 160 mg</title>
          <description>Participants received once daily oral dose of GSK525762 60 mg in combination with enzalutamide 160 mg up to maximum of 21.3 months.</description>
        </group>
        <group group_id="B6">
          <title>GSK525762 60 mg Alternate+Enzalutamide 160 mg</title>
          <description>Participants received an alternate dosing schedule- once daily GSK525762 60 mg + enzalutamide 160 mg tablets via the oral route for 2 weeks followed by 1 week off-treatment up to maximum of 21.3 months.</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="4"/>
            <count group_id="B4" value="10"/>
            <count group_id="B5" value="22"/>
            <count group_id="B6" value="21"/>
            <count group_id="B7" value="73"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70.4" spread="7.69"/>
                    <measurement group_id="B2" value="68.0" spread="9.57"/>
                    <measurement group_id="B3" value="76.3" spread="4.11"/>
                    <measurement group_id="B4" value="69.3" spread="4.72"/>
                    <measurement group_id="B5" value="71.0" spread="6.49"/>
                    <measurement group_id="B6" value="69.1" spread="5.11"/>
                    <measurement group_id="B7" value="70.2" spread="6.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="22"/>
                    <measurement group_id="B6" value="21"/>
                    <measurement group_id="B7" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Asian-East Asian Heritage</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White-Arabic/North African Heritage</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White-White/Caucasian/European Heritage</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="21"/>
                    <measurement group_id="B6" value="19"/>
                    <measurement group_id="B7" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Any Adverse Events (AEs) and Serious Adverse Events (SAEs)</title>
        <description>An AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose: results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, any other situation according to medical or scientific judgement, or is associated with liver injury and impaired liver function.</description>
        <time_frame>Up to 21.3 months</time_frame>
        <population>All Treated Population consisted of all participants who received at least one dose of GSK525762 or abiraterone or enzalutamide.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK525762 60 mg+Abiraterone 1000 mg</title>
            <description>Participants received once daily oral dose of GSK525762 60 milligram (mg) in combination with abiraterone 1000 mg up to maximum of 21.3 months. Participants received prednisone 5 mg orally twice daily as per abiraterone label.</description>
          </group>
          <group group_id="O2">
            <title>GSK525762 60 mg Alternate+Abiraterone 1000 mg</title>
            <description>Participants received an alternate dosing schedule- once daily GSK525762 60 mg + abiraterone 1000 mg tablets via the oral route for 2 weeks followed by 1 week off-treatment up to maximum of 21.3 months. Participants received prednisone 5 mg orally twice daily as per abiraterone label.</description>
          </group>
          <group group_id="O3">
            <title>GSK525762 40 mg+Abiraterone 1000 mg</title>
            <description>Participants received once daily oral dose of GSK525762 40 mg in combination with abiraterone 1000 mg up to maximum of 21.3 months. Participants received prednisone 5 mg orally twice daily as per abiraterone label.</description>
          </group>
          <group group_id="O4">
            <title>GSK525762 80 mg+Enzalutamide 160 mg</title>
            <description>Participants received once daily oral dose of GSK525762 80 mg in combination with enzalutamide 160 mg up to maximum of 21.3 months.</description>
          </group>
          <group group_id="O5">
            <title>GSK525762 60 mg+Enzalutamide 160 mg</title>
            <description>Participants received once daily oral dose of GSK525762 60 mg in combination with enzalutamide 160 mg up to maximum of 21.3 months.</description>
          </group>
          <group group_id="O6">
            <title>GSK525762 60 mg Alternate+Enzalutamide 160 mg</title>
            <description>Participants received an alternate dosing schedule- once daily GSK525762 60 mg + enzalutamide 160 mg tablets via the oral route for 2 weeks followed by 1 week off-treatment up to maximum of 21.3 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Any Adverse Events (AEs) and Serious Adverse Events (SAEs)</title>
          <description>An AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose: results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, any other situation according to medical or scientific judgement, or is associated with liver injury and impaired liver function.</description>
          <population>All Treated Population consisted of all participants who received at least one dose of GSK525762 or abiraterone or enzalutamide.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="22"/>
                <count group_id="O6" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="10"/>
                    <measurement group_id="O5" value="22"/>
                    <measurement group_id="O6" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With AEs Leading to Any Dose Reduction or Delays</title>
        <description>An AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Number of participants with AEs leading to any dose reduction or delays have been presented.</description>
        <time_frame>Up to 21.3 months</time_frame>
        <population>All Treated Population.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK525762 60 mg+Abiraterone 1000 mg</title>
            <description>Participants received once daily oral dose of GSK525762 60 milligram (mg) in combination with abiraterone 1000 mg up to maximum of 21.3 months. Participants received prednisone 5 mg orally twice daily as per abiraterone label.</description>
          </group>
          <group group_id="O2">
            <title>GSK525762 60 mg Alternate+Abiraterone 1000 mg</title>
            <description>Participants received an alternate dosing schedule- once daily GSK525762 60 mg + abiraterone 1000 mg tablets via the oral route for 2 weeks followed by 1 week off-treatment up to maximum of 21.3 months. Participants received prednisone 5 mg orally twice daily as per abiraterone label.</description>
          </group>
          <group group_id="O3">
            <title>GSK525762 40 mg+Abiraterone 1000 mg</title>
            <description>Participants received once daily oral dose of GSK525762 40 mg in combination with abiraterone 1000 mg up to maximum of 21.3 months. Participants received prednisone 5 mg orally twice daily as per abiraterone label.</description>
          </group>
          <group group_id="O4">
            <title>GSK525762 80 mg+Enzalutamide 160 mg</title>
            <description>Participants received once daily oral dose of GSK525762 80 mg in combination with enzalutamide 160 mg up to maximum of 21.3 months.</description>
          </group>
          <group group_id="O5">
            <title>GSK525762 60 mg+Enzalutamide 160 mg</title>
            <description>Participants received once daily oral dose of GSK525762 60 mg in combination with enzalutamide 160 mg up to maximum of 21.3 months.</description>
          </group>
          <group group_id="O6">
            <title>GSK525762 60 mg Alternate+Enzalutamide 160 mg</title>
            <description>Participants received an alternate dosing schedule- once daily GSK525762 60 mg + enzalutamide 160 mg tablets via the oral route for 2 weeks followed by 1 week off-treatment up to maximum of 21.3 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With AEs Leading to Any Dose Reduction or Delays</title>
          <description>An AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Number of participants with AEs leading to any dose reduction or delays have been presented.</description>
          <population>All Treated Population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="22"/>
                <count group_id="O6" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Dose reduction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="10"/>
                    <measurement group_id="O6" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dose delay</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="15"/>
                    <measurement group_id="O6" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Withdrew Due to Toxicity and Changes in Safety Assessment</title>
        <description>Number of participants who withdrew due to toxicity and changes in safety assessment including laboratory parameters and vital signs have been presented.</description>
        <time_frame>Up to 21.3 months</time_frame>
        <population>All Treated Population.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK525762 60 mg+Abiraterone 1000 mg</title>
            <description>Participants received once daily oral dose of GSK525762 60 milligram (mg) in combination with abiraterone 1000 mg up to maximum of 21.3 months. Participants received prednisone 5 mg orally twice daily as per abiraterone label.</description>
          </group>
          <group group_id="O2">
            <title>GSK525762 60 mg Alternate+Abiraterone 1000 mg</title>
            <description>Participants received an alternate dosing schedule- once daily GSK525762 60 mg + abiraterone 1000 mg tablets via the oral route for 2 weeks followed by 1 week off-treatment up to maximum of 21.3 months. Participants received prednisone 5 mg orally twice daily as per abiraterone label.</description>
          </group>
          <group group_id="O3">
            <title>GSK525762 40 mg+Abiraterone 1000 mg</title>
            <description>Participants received once daily oral dose of GSK525762 40 mg in combination with abiraterone 1000 mg up to maximum of 21.3 months. Participants received prednisone 5 mg orally twice daily as per abiraterone label.</description>
          </group>
          <group group_id="O4">
            <title>GSK525762 80 mg+Enzalutamide 160 mg</title>
            <description>Participants received once daily oral dose of GSK525762 80 mg in combination with enzalutamide 160 mg up to maximum of 21.3 months.</description>
          </group>
          <group group_id="O5">
            <title>GSK525762 60 mg+Enzalutamide 160 mg</title>
            <description>Participants received once daily oral dose of GSK525762 60 mg in combination with enzalutamide 160 mg up to maximum of 21.3 months.</description>
          </group>
          <group group_id="O6">
            <title>GSK525762 60 mg Alternate+Enzalutamide 160 mg</title>
            <description>Participants received an alternate dosing schedule- once daily GSK525762 60 mg + enzalutamide 160 mg tablets via the oral route for 2 weeks followed by 1 week off-treatment up to maximum of 21.3 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Withdrew Due to Toxicity and Changes in Safety Assessment</title>
          <description>Number of participants who withdrew due to toxicity and changes in safety assessment including laboratory parameters and vital signs have been presented.</description>
          <population>All Treated Population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="22"/>
                <count group_id="O6" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="8"/>
                    <measurement group_id="O6" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With &gt;=50 Percent (%) Decrease in Prostate-specific Antigen From Baseline (PSA50)</title>
        <description>PSA50 response rate is defined as percentage of participants with a decrease of &gt;=50% in the PSA concentration from the Baseline PSA value determined at least 12 weeks after start of treatment and confirmed &gt;=4 weeks later by an additional PSA evaluation.</description>
        <time_frame>Up to 21.3 months</time_frame>
        <population>Modified All Treated Population comprised of all participants who received at least one dose of GSK525762 plus abiraterone/enzalutamide. Only those participants with data available at the indicated time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK525762 60 mg+Abiraterone 1000 mg</title>
            <description>Participants received once daily oral dose of GSK525762 60 milligram (mg) in combination with abiraterone 1000 mg up to maximum of 21.3 months. Participants received prednisone 5 mg orally twice daily as per abiraterone label.</description>
          </group>
          <group group_id="O2">
            <title>GSK525762 60 mg Alternate+Abiraterone 1000 mg</title>
            <description>Participants received an alternate dosing schedule- once daily GSK525762 60 mg + abiraterone 1000 mg tablets via the oral route for 2 weeks followed by 1 week off-treatment up to maximum of 21.3 months. Participants received prednisone 5 mg orally twice daily as per abiraterone label.</description>
          </group>
          <group group_id="O3">
            <title>GSK525762 40 mg+Abiraterone 1000 mg</title>
            <description>Participants received once daily oral dose of GSK525762 40 mg in combination with abiraterone 1000 mg up to maximum of 21.3 months. Participants received prednisone 5 mg orally twice daily as per abiraterone label.</description>
          </group>
          <group group_id="O4">
            <title>GSK525762 80 mg+Enzalutamide 160 mg</title>
            <description>Participants received once daily oral dose of GSK525762 80 mg in combination with enzalutamide 160 mg up to maximum of 21.3 months.</description>
          </group>
          <group group_id="O5">
            <title>GSK525762 60 mg+Enzalutamide 160 mg</title>
            <description>Participants received once daily oral dose of GSK525762 60 mg in combination with enzalutamide 160 mg up to maximum of 21.3 months.</description>
          </group>
          <group group_id="O6">
            <title>GSK525762 60 mg Alternate+Enzalutamide 160 mg</title>
            <description>Participants received an alternate dosing schedule- once daily GSK525762 60 mg + enzalutamide 160 mg tablets via the oral route for 2 weeks followed by 1 week off-treatment up to maximum of 21.3 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With &gt;=50 Percent (%) Decrease in Prostate-specific Antigen From Baseline (PSA50)</title>
          <description>PSA50 response rate is defined as percentage of participants with a decrease of &gt;=50% in the PSA concentration from the Baseline PSA value determined at least 12 weeks after start of treatment and confirmed &gt;=4 weeks later by an additional PSA evaluation.</description>
          <population>Modified All Treated Population comprised of all participants who received at least one dose of GSK525762 plus abiraterone/enzalutamide. Only those participants with data available at the indicated time points were analyzed.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="19"/>
                <count group_id="O6" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0.0" upper_limit="30.8"/>
                    <measurement group_id="O2" value="0" lower_limit="0.0" upper_limit="45.9"/>
                    <measurement group_id="O3" value="0" lower_limit="0.0" upper_limit="60.2"/>
                    <measurement group_id="O4" value="0" lower_limit="0.0" upper_limit="30.8"/>
                    <measurement group_id="O5" value="0" lower_limit="0.0" upper_limit="17.6"/>
                    <measurement group_id="O6" value="0" lower_limit="0.0" upper_limit="16.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Observed Plasma Concentration (Cmax) of GSK525762 and Its Active Metabolites GSK3529246</title>
        <description>Blood samples were collected at indicated time points for pharmacokinetic (PK) analysis of GSK525762 and GSK3529246 (metabolite of GSK525762). PK parameters were calculated using standard non-compartmental analysis. PK Population consisted of all participants from the All Treated Safety Population for whom a PK sample was obtained and analyzed.</description>
        <time_frame>Day 1: Pre-dose, 30 minutes, 1, 3, 6 to 12, 24 hours post-dose on Weeks 1 and 3</time_frame>
        <population>PK Population. Only those participants with data available at the indicated time points were analyzed (indicated by n=X in category titles).</population>
        <group_list>
          <group group_id="O1">
            <title>GSK525762 60 mg+Abiraterone 1000 mg</title>
            <description>Participants received once daily oral dose of GSK525762 60 milligram (mg) in combination with abiraterone 1000 mg up to maximum of 21.3 months. Participants received prednisone 5 mg orally twice daily as per abiraterone label.</description>
          </group>
          <group group_id="O2">
            <title>GSK525762 60 mg Alternate+Abiraterone 1000 mg</title>
            <description>Participants received an alternate dosing schedule- once daily GSK525762 60 mg + abiraterone 1000 mg tablets via the oral route for 2 weeks followed by 1 week off-treatment up to maximum of 21.3 months. Participants received prednisone 5 mg orally twice daily as per abiraterone label.</description>
          </group>
          <group group_id="O3">
            <title>GSK525762 40 mg+Abiraterone 1000 mg</title>
            <description>Participants received once daily oral dose of GSK525762 40 mg in combination with abiraterone 1000 mg up to maximum of 21.3 months. Participants received prednisone 5 mg orally twice daily as per abiraterone label.</description>
          </group>
          <group group_id="O4">
            <title>GSK525762 80 mg+Enzalutamide 160 mg</title>
            <description>Participants received once daily oral dose of GSK525762 80 mg in combination with enzalutamide 160 mg up to maximum of 21.3 months.</description>
          </group>
          <group group_id="O5">
            <title>GSK525762 60 mg+Enzalutamide 160 mg</title>
            <description>Participants received once daily oral dose of GSK525762 60 mg in combination with enzalutamide 160 mg up to maximum of 21.3 months.</description>
          </group>
          <group group_id="O6">
            <title>GSK525762 60 mg Alternate+Enzalutamide 160 mg</title>
            <description>Participants received an alternate dosing schedule- once daily GSK525762 60 mg + enzalutamide 160 mg tablets via the oral route for 2 weeks followed by 1 week off-treatment up to maximum of 21.3 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Observed Plasma Concentration (Cmax) of GSK525762 and Its Active Metabolites GSK3529246</title>
          <description>Blood samples were collected at indicated time points for pharmacokinetic (PK) analysis of GSK525762 and GSK3529246 (metabolite of GSK525762). PK parameters were calculated using standard non-compartmental analysis. PK Population consisted of all participants from the All Treated Safety Population for whom a PK sample was obtained and analyzed.</description>
          <population>PK Population. Only those participants with data available at the indicated time points were analyzed (indicated by n=X in category titles).</population>
          <units>Nanogram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="21"/>
                <count group_id="O6" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>GSK525762:Week1 Day1,n=10,6,4,10,21,18</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="21"/>
                    <count group_id="O6" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="950.319" spread="19.18"/>
                    <measurement group_id="O2" value="993.154" spread="33.77"/>
                    <measurement group_id="O3" value="671.129" spread="30.44"/>
                    <measurement group_id="O4" value="427.580" spread="31.76"/>
                    <measurement group_id="O5" value="333.256" spread="48.86"/>
                    <measurement group_id="O6" value="336.296" spread="43.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK525762:Week3 Day1,n=4,3,3,9,17,10</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="17"/>
                    <count group_id="O6" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="891.302" spread="36.79"/>
                    <measurement group_id="O2" value="735.171" spread="21.63"/>
                    <measurement group_id="O3" value="559.711" spread="40.59"/>
                    <measurement group_id="O4" value="284.298" spread="45.12"/>
                    <measurement group_id="O5" value="158.409" spread="153.45"/>
                    <measurement group_id="O6" value="171.527" spread="47.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK3529246:Week1 Day1,n=10,6,4,10,21,18</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="21"/>
                    <count group_id="O6" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="280.892" spread="43.14"/>
                    <measurement group_id="O2" value="318.772" spread="31.13"/>
                    <measurement group_id="O3" value="199.456" spread="32.94"/>
                    <measurement group_id="O4" value="408.208" spread="39.86"/>
                    <measurement group_id="O5" value="321.750" spread="24.24"/>
                    <measurement group_id="O6" value="323.685" spread="25.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK3529246:Week3 Day1,n=4,3,3,10,17,10</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="17"/>
                    <count group_id="O6" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="447.929" spread="39.30"/>
                    <measurement group_id="O2" value="444.232" spread="26.74"/>
                    <measurement group_id="O3" value="364.151" spread="15.46"/>
                    <measurement group_id="O4" value="449.614" spread="49.54"/>
                    <measurement group_id="O5" value="328.398" spread="39.74"/>
                    <measurement group_id="O6" value="356.615" spread="18.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Cmax (Tmax) of GSK525762 and Its Active Metabolites GSK3529246</title>
        <description>Blood samples were collected at indicated time points for PK analysis of GSK525762 and GSK3529246 (metabolite of GSK525762). PK parameters were calculated using standard non-compartmental analysis.</description>
        <time_frame>Day 1: Pre-dose, 30 minutes, 1, 3, 6 to 12, 24 hours post-dose on Weeks 1 and 3</time_frame>
        <population>PK Population. Only those participants with data available at the indicated time points were analyzed (indicated by n=X in category titles).</population>
        <group_list>
          <group group_id="O1">
            <title>GSK525762 60 mg+Abiraterone 1000 mg</title>
            <description>Participants received once daily oral dose of GSK525762 60 milligram (mg) in combination with abiraterone 1000 mg up to maximum of 21.3 months. Participants received prednisone 5 mg orally twice daily as per abiraterone label.</description>
          </group>
          <group group_id="O2">
            <title>GSK525762 60 mg Alternate+Abiraterone 1000 mg</title>
            <description>Participants received an alternate dosing schedule- once daily GSK525762 60 mg + abiraterone 1000 mg tablets via the oral route for 2 weeks followed by 1 week off-treatment up to maximum of 21.3 months. Participants received prednisone 5 mg orally twice daily as per abiraterone label.</description>
          </group>
          <group group_id="O3">
            <title>GSK525762 40 mg+Abiraterone 1000 mg</title>
            <description>Participants received once daily oral dose of GSK525762 40 mg in combination with abiraterone 1000 mg up to maximum of 21.3 months. Participants received prednisone 5 mg orally twice daily as per abiraterone label.</description>
          </group>
          <group group_id="O4">
            <title>GSK525762 80 mg+Enzalutamide 160 mg</title>
            <description>Participants received once daily oral dose of GSK525762 80 mg in combination with enzalutamide 160 mg up to maximum of 21.3 months.</description>
          </group>
          <group group_id="O5">
            <title>GSK525762 60 mg+Enzalutamide 160 mg</title>
            <description>Participants received once daily oral dose of GSK525762 60 mg in combination with enzalutamide 160 mg up to maximum of 21.3 months.</description>
          </group>
          <group group_id="O6">
            <title>GSK525762 60 mg Alternate+Enzalutamide 160 mg</title>
            <description>Participants received an alternate dosing schedule- once daily GSK525762 60 mg + enzalutamide 160 mg tablets via the oral route for 2 weeks followed by 1 week off-treatment up to maximum of 21.3 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Cmax (Tmax) of GSK525762 and Its Active Metabolites GSK3529246</title>
          <description>Blood samples were collected at indicated time points for PK analysis of GSK525762 and GSK3529246 (metabolite of GSK525762). PK parameters were calculated using standard non-compartmental analysis.</description>
          <population>PK Population. Only those participants with data available at the indicated time points were analyzed (indicated by n=X in category titles).</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="21"/>
                <count group_id="O6" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>GSK525762:Week1 Day1,n=10,6,4,10,21,18</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="21"/>
                    <count group_id="O6" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.800" lower_limit="0.50" upper_limit="2.92"/>
                    <measurement group_id="O2" value="0.558" lower_limit="0.50" upper_limit="1.00"/>
                    <measurement group_id="O3" value="1.000" lower_limit="0.58" upper_limit="3.08"/>
                    <measurement group_id="O4" value="0.508" lower_limit="0.40" upper_limit="1.08"/>
                    <measurement group_id="O5" value="1.000" lower_limit="0.45" upper_limit="3.00"/>
                    <measurement group_id="O6" value="0.742" lower_limit="0.50" upper_limit="6.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK525762:Week3 Day1,n=4,3,3,9,17,10</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="17"/>
                    <count group_id="O6" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.500" lower_limit="0.50" upper_limit="0.50"/>
                    <measurement group_id="O2" value="1.000" lower_limit="0.50" upper_limit="3.00"/>
                    <measurement group_id="O3" value="0.950" lower_limit="0.50" upper_limit="1.00"/>
                    <measurement group_id="O4" value="0.583" lower_limit="0.47" upper_limit="3.00"/>
                    <measurement group_id="O5" value="0.933" lower_limit="0.00" upper_limit="3.03"/>
                    <measurement group_id="O6" value="0.517" lower_limit="0.50" upper_limit="3.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK3529246:Week1 Day1,n=10,6,4,10,21,18</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="21"/>
                    <count group_id="O6" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.000" lower_limit="1.18" upper_limit="6.00"/>
                    <measurement group_id="O2" value="3.000" lower_limit="0.53" upper_limit="6.00"/>
                    <measurement group_id="O3" value="2.042" lower_limit="1.00" upper_limit="3.08"/>
                    <measurement group_id="O4" value="2.067" lower_limit="1.00" upper_limit="3.00"/>
                    <measurement group_id="O5" value="2.917" lower_limit="0.53" upper_limit="6.05"/>
                    <measurement group_id="O6" value="1.817" lower_limit="0.95" upper_limit="6.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK3529246:Week3 Day1,n=4,3,3,10,17,10</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="17"/>
                    <count group_id="O6" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.000" lower_limit="0.85" upper_limit="3.00"/>
                    <measurement group_id="O2" value="3.000" lower_limit="1.00" upper_limit="6.17"/>
                    <measurement group_id="O3" value="3.000" lower_limit="1.00" upper_limit="3.03"/>
                    <measurement group_id="O4" value="1.042" lower_limit="0.50" upper_limit="6.00"/>
                    <measurement group_id="O5" value="1.017" lower_limit="0.00" upper_limit="6.00"/>
                    <measurement group_id="O6" value="1.875" lower_limit="0.50" upper_limit="6.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Plasma Concentration-time Curve From Time Zero to the End of the Dosing Interval (AUC[0-tau]) of GSK525762 and Its Active Metabolites GSK3529246</title>
        <description>Blood samples were collected at indicated time points for PK analysis of GSK525762 and GSK3529246 (metabolite of GSK525762). PK parameters were calculated using standard non-compartmental analysis.</description>
        <time_frame>Day 1: Pre-dose, 30 minutes, 1, 3, 6 to 12, 24 hours post-dose on Weeks 1 and 3</time_frame>
        <population>PK Population. Only those participants with data available at the indicated time points were analyzed (indicated by n=X in category titles).</population>
        <group_list>
          <group group_id="O1">
            <title>GSK525762 60 mg+Abiraterone 1000 mg</title>
            <description>Participants received once daily oral dose of GSK525762 60 milligram (mg) in combination with abiraterone 1000 mg up to maximum of 21.3 months. Participants received prednisone 5 mg orally twice daily as per abiraterone label.</description>
          </group>
          <group group_id="O2">
            <title>GSK525762 60 mg Alternate+Abiraterone 1000 mg</title>
            <description>Participants received an alternate dosing schedule- once daily GSK525762 60 mg + abiraterone 1000 mg tablets via the oral route for 2 weeks followed by 1 week off-treatment up to maximum of 21.3 months. Participants received prednisone 5 mg orally twice daily as per abiraterone label.</description>
          </group>
          <group group_id="O3">
            <title>GSK525762 40 mg+Abiraterone 1000 mg</title>
            <description>Participants received once daily oral dose of GSK525762 40 mg in combination with abiraterone 1000 mg up to maximum of 21.3 months. Participants received prednisone 5 mg orally twice daily as per abiraterone label.</description>
          </group>
          <group group_id="O4">
            <title>GSK525762 80 mg+Enzalutamide 160 mg</title>
            <description>Participants received once daily oral dose of GSK525762 80 mg in combination with enzalutamide 160 mg up to maximum of 21.3 months.</description>
          </group>
          <group group_id="O5">
            <title>GSK525762 60 mg+Enzalutamide 160 mg</title>
            <description>Participants received once daily oral dose of GSK525762 60 mg in combination with enzalutamide 160 mg up to maximum of 21.3 months.</description>
          </group>
          <group group_id="O6">
            <title>GSK525762 60 mg Alternate+Enzalutamide 160 mg</title>
            <description>Participants received an alternate dosing schedule- once daily GSK525762 60 mg + enzalutamide 160 mg tablets via the oral route for 2 weeks followed by 1 week off-treatment up to maximum of 21.3 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration-time Curve From Time Zero to the End of the Dosing Interval (AUC[0-tau]) of GSK525762 and Its Active Metabolites GSK3529246</title>
          <description>Blood samples were collected at indicated time points for PK analysis of GSK525762 and GSK3529246 (metabolite of GSK525762). PK parameters were calculated using standard non-compartmental analysis.</description>
          <population>PK Population. Only those participants with data available at the indicated time points were analyzed (indicated by n=X in category titles).</population>
          <units>Hours*nanogram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="12"/>
                <count group_id="O6" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>GSK525762:Week1 Day1,n=8,2,2,6,9,8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="9"/>
                    <count group_id="O6" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4927.834" spread="71.78"/>
                    <measurement group_id="O2" value="4677.411" spread="21.59"/>
                    <measurement group_id="O3" value="4172.282" spread="31.08"/>
                    <measurement group_id="O4" value="1139.481" spread="34.32"/>
                    <measurement group_id="O5" value="1261.529" spread="102.14"/>
                    <measurement group_id="O6" value="959.452" spread="60.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK525762:Week3 Day1,n=4,1,3,5,6,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2697.923" spread="69.10"/>
                    <measurement group_id="O2" value="2580.877" spread="NA">Geometric coefficient of variation could not be calculated for a single participant.</measurement>
                    <measurement group_id="O3" value="1561.908" spread="13.67"/>
                    <measurement group_id="O4" value="674.437" spread="57.10"/>
                    <measurement group_id="O5" value="660.607" spread="14.41"/>
                    <measurement group_id="O6" value="386.950" spread="37.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK3529246:Week1 Day1,n=2,1,0,5,9,10</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="9"/>
                    <count group_id="O6" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3765.196" spread="0.47"/>
                    <measurement group_id="O2" value="4918.549" spread="NA">Geometric coefficient of variation could not be calculated for a single participant.</measurement>
                    <measurement group_id="O4" value="4379.342" spread="30.76"/>
                    <measurement group_id="O5" value="3373.990" spread="19.73"/>
                    <measurement group_id="O6" value="3306.018" spread="31.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK3529246:Week3 Day1,n=2,2,2,4,12,7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="4"/>
                    <count group_id="O5" value="12"/>
                    <count group_id="O6" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4170.516" spread="6.55"/>
                    <measurement group_id="O2" value="5146.749" spread="9.99"/>
                    <measurement group_id="O3" value="4598.235" spread="16.28"/>
                    <measurement group_id="O4" value="3816.407" spread="37.02"/>
                    <measurement group_id="O5" value="3386.702" spread="30.44"/>
                    <measurement group_id="O6" value="3082.516" spread="33.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough Concentration (Ctrough) of GSK525762 and Its Active Metabolites GSK3529246</title>
        <description>Blood samples were collected at indicated time points for PK analysis of GSK525762 and GSK3529246 (metabolite of GSK525762). PK parameters were calculated using standard non-compartmental analysis.</description>
        <time_frame>Day 1: Pre-dose, 30 minutes, 1, 3, 6 to 12, 24 hours post-dose on Weeks 1 and 3</time_frame>
        <population>PK Population. Only those participants with data available at the indicated time points were analyzed (indicated by n=X in category titles).</population>
        <group_list>
          <group group_id="O1">
            <title>GSK525762 60 mg+Abiraterone 1000 mg</title>
            <description>Participants received once daily oral dose of GSK525762 60 milligram (mg) in combination with abiraterone 1000 mg up to maximum of 21.3 months. Participants received prednisone 5 mg orally twice daily as per abiraterone label.</description>
          </group>
          <group group_id="O2">
            <title>GSK525762 60 mg Alternate+Abiraterone 1000 mg</title>
            <description>Participants received an alternate dosing schedule- once daily GSK525762 60 mg + abiraterone 1000 mg tablets via the oral route for 2 weeks followed by 1 week off-treatment up to maximum of 21.3 months. Participants received prednisone 5 mg orally twice daily as per abiraterone label.</description>
          </group>
          <group group_id="O3">
            <title>GSK525762 40 mg+Abiraterone 1000 mg</title>
            <description>Participants received once daily oral dose of GSK525762 40 mg in combination with abiraterone 1000 mg up to maximum of 21.3 months. Participants received prednisone 5 mg orally twice daily as per abiraterone label.</description>
          </group>
          <group group_id="O4">
            <title>GSK525762 80 mg+Enzalutamide 160 mg</title>
            <description>Participants received once daily oral dose of GSK525762 80 mg in combination with enzalutamide 160 mg up to maximum of 21.3 months.</description>
          </group>
          <group group_id="O5">
            <title>GSK525762 60 mg+Enzalutamide 160 mg</title>
            <description>Participants received once daily oral dose of GSK525762 60 mg in combination with enzalutamide 160 mg up to maximum of 21.3 months.</description>
          </group>
          <group group_id="O6">
            <title>GSK525762 60 mg Alternate+Enzalutamide 160 mg</title>
            <description>Participants received an alternate dosing schedule- once daily GSK525762 60 mg + enzalutamide 160 mg tablets via the oral route for 2 weeks followed by 1 week off-treatment up to maximum of 21.3 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Trough Concentration (Ctrough) of GSK525762 and Its Active Metabolites GSK3529246</title>
          <description>Blood samples were collected at indicated time points for PK analysis of GSK525762 and GSK3529246 (metabolite of GSK525762). PK parameters were calculated using standard non-compartmental analysis.</description>
          <population>PK Population. Only those participants with data available at the indicated time points were analyzed (indicated by n=X in category titles).</population>
          <units>Nanogram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="20"/>
                <count group_id="O6" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>GSK525762:Week1 Day1,n=8,2,3,1,3,4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="1"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.418" spread="192.37"/>
                    <measurement group_id="O2" value="8.696" spread="72.93"/>
                    <measurement group_id="O3" value="13.664" spread="119.83"/>
                    <measurement group_id="O4" value="2.100" spread="NA">Geometric coefficient of variation could not be calculated for a single participant.</measurement>
                    <measurement group_id="O5" value="5.053" spread="3035.92"/>
                    <measurement group_id="O6" value="1.660" spread="34.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK525762:Week3 Day1,n=2,2,2,1,0,0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="1"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.966" spread="93.46"/>
                    <measurement group_id="O2" value="4.555" spread="522.90"/>
                    <measurement group_id="O3" value="1.410" spread="48.34"/>
                    <measurement group_id="O4" value="3.540" spread="NA">Geometric coefficient of variation could not be calculated for a single participant.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK3529246:Week1 Day1,n=8,3,3,9,20,17</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="20"/>
                    <count group_id="O6" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.995" spread="52.50"/>
                    <measurement group_id="O2" value="68.379" spread="47.51"/>
                    <measurement group_id="O3" value="42.107" spread="52.26"/>
                    <measurement group_id="O4" value="46.011" spread="38.73"/>
                    <measurement group_id="O5" value="37.765" spread="56.41"/>
                    <measurement group_id="O6" value="38.200" spread="53.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK3529246:Week3 Day1,n=3,3,2,7,13,8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.223" spread="99.09"/>
                    <measurement group_id="O2" value="48.291" spread="29.86"/>
                    <measurement group_id="O3" value="63.526" spread="3.90"/>
                    <measurement group_id="O4" value="50.882" spread="77.10"/>
                    <measurement group_id="O5" value="32.299" spread="60.18"/>
                    <measurement group_id="O6" value="26.165" spread="76.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cmax of Abiraterone</title>
        <description>Blood samples were collected at indicated time points for PK analysis of abiraterone. PK parameters were calculated using standard non-compartmental analysis.</description>
        <time_frame>Day 1: Pre-dose, 30 minutes, 1, 3, 6 to 12, 24 hours post-dose on Weeks 1 and 3</time_frame>
        <population>PK Population. Only those participants with data available at the indicated time points were analyzed (indicated by n=X in category titles).</population>
        <group_list>
          <group group_id="O1">
            <title>GSK525762 60 mg+Abiraterone 1000 mg</title>
            <description>Participants received once daily oral dose of GSK525762 60 milligram (mg) in combination with abiraterone 1000 mg up to maximum of 21.3 months. Participants received prednisone 5 mg orally twice daily as per abiraterone label.</description>
          </group>
          <group group_id="O2">
            <title>GSK525762 60 mg Alternate+Abiraterone 1000 mg</title>
            <description>Participants received an alternate dosing schedule- once daily GSK525762 60 mg + abiraterone 1000 mg tablets via the oral route for 2 weeks followed by 1 week off-treatment up to maximum of 21.3 months. Participants received prednisone 5 mg orally twice daily as per abiraterone label.</description>
          </group>
          <group group_id="O3">
            <title>GSK525762 40 mg+Abiraterone 1000 mg</title>
            <description>Participants received once daily oral dose of GSK525762 40 mg in combination with abiraterone 1000 mg up to maximum of 21.3 months. Participants received prednisone 5 mg orally twice daily as per abiraterone label.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax of Abiraterone</title>
          <description>Blood samples were collected at indicated time points for PK analysis of abiraterone. PK parameters were calculated using standard non-compartmental analysis.</description>
          <population>PK Population. Only those participants with data available at the indicated time points were analyzed (indicated by n=X in category titles).</population>
          <units>Nanogram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1 Day 1, n=10,5,4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.962" spread="57.07"/>
                    <measurement group_id="O2" value="63.369" spread="114.31"/>
                    <measurement group_id="O3" value="122.496" spread="131.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3 Day 1, n=4,4,2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="149.673" spread="65.39"/>
                    <measurement group_id="O2" value="87.554" spread="110.92"/>
                    <measurement group_id="O3" value="146.924" spread="76.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tmax of Abiraterone</title>
        <description>Blood samples were collected at indicated time points for PK analysis of abiraterone. PK parameters were calculated using standard non-compartmental analysis.</description>
        <time_frame>Day 1: Pre-dose, 30 minutes, 1, 3, 6 to 12, 24 hours post-dose on Weeks 1 and 3</time_frame>
        <population>PK Population. Only those participants with data available at the indicated time points were analyzed (indicated by n=X in category titles).</population>
        <group_list>
          <group group_id="O1">
            <title>GSK525762 60 mg+Abiraterone 1000 mg</title>
            <description>Participants received once daily oral dose of GSK525762 60 milligram (mg) in combination with abiraterone 1000 mg up to maximum of 21.3 months. Participants received prednisone 5 mg orally twice daily as per abiraterone label.</description>
          </group>
          <group group_id="O2">
            <title>GSK525762 60 mg Alternate+Abiraterone 1000 mg</title>
            <description>Participants received an alternate dosing schedule- once daily GSK525762 60 mg + abiraterone 1000 mg tablets via the oral route for 2 weeks followed by 1 week off-treatment up to maximum of 21.3 months. Participants received prednisone 5 mg orally twice daily as per abiraterone label.</description>
          </group>
          <group group_id="O3">
            <title>GSK525762 40 mg+Abiraterone 1000 mg</title>
            <description>Participants received once daily oral dose of GSK525762 40 mg in combination with abiraterone 1000 mg up to maximum of 21.3 months. Participants received prednisone 5 mg orally twice daily as per abiraterone label.</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax of Abiraterone</title>
          <description>Blood samples were collected at indicated time points for PK analysis of abiraterone. PK parameters were calculated using standard non-compartmental analysis.</description>
          <population>PK Population. Only those participants with data available at the indicated time points were analyzed (indicated by n=X in category titles).</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1 Day 1, n=10,5,4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.133" lower_limit="0.17" upper_limit="3.13"/>
                    <measurement group_id="O2" value="1.083" lower_limit="0.53" upper_limit="3.00"/>
                    <measurement group_id="O3" value="0.750" lower_limit="0.00" upper_limit="1.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3 Day 1, n=4,4,2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.000" lower_limit="0.85" upper_limit="1.00"/>
                    <measurement group_id="O2" value="2.000" lower_limit="0.98" upper_limit="3.00"/>
                    <measurement group_id="O3" value="3.017" lower_limit="3.00" upper_limit="3.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC(0-tau) of Abiraterone</title>
        <description>Blood samples were collected at indicated time points for PK analysis of abiraterone. PK parameters were calculated using standard non-compartmental analysis.</description>
        <time_frame>Day 1: Pre-dose, 30 minutes, 1, 3, 6 to 12, 24 hours post-dose on Weeks 1 and 3</time_frame>
        <population>PK Population. Only those participants with data available at the indicated time points were analyzed (indicated by n=X in category titles).</population>
        <group_list>
          <group group_id="O1">
            <title>GSK525762 60 mg+Abiraterone 1000 mg</title>
            <description>Participants received once daily oral dose of GSK525762 60 milligram (mg) in combination with abiraterone 1000 mg up to maximum of 21.3 months. Participants received prednisone 5 mg orally twice daily as per abiraterone label.</description>
          </group>
          <group group_id="O2">
            <title>GSK525762 60 mg Alternate+Abiraterone 1000 mg</title>
            <description>Participants received an alternate dosing schedule- once daily GSK525762 60 mg + abiraterone 1000 mg tablets via the oral route for 2 weeks followed by 1 week off-treatment up to maximum of 21.3 months. Participants received prednisone 5 mg orally twice daily as per abiraterone label.</description>
          </group>
          <group group_id="O3">
            <title>GSK525762 40 mg+Abiraterone 1000 mg</title>
            <description>Participants received once daily oral dose of GSK525762 40 mg in combination with abiraterone 1000 mg up to maximum of 21.3 months. Participants received prednisone 5 mg orally twice daily as per abiraterone label.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC(0-tau) of Abiraterone</title>
          <description>Blood samples were collected at indicated time points for PK analysis of abiraterone. PK parameters were calculated using standard non-compartmental analysis.</description>
          <population>PK Population. Only those participants with data available at the indicated time points were analyzed (indicated by n=X in category titles).</population>
          <units>Hours*nanogram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1 Day 1, n=5,1,1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="432.368" spread="56.74"/>
                    <measurement group_id="O2" value="148.871" spread="NA">Geometric coefficient of variation could not be calculated for a single participant.</measurement>
                    <measurement group_id="O3" value="1405.809" spread="NA">Geometric coefficient of variation could not be calculated for a single participant.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3 Day 1, n=1,2,1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1361.627" spread="NA">Geometric coefficient of variation could not be calculated for a single participant.</measurement>
                    <measurement group_id="O2" value="595.686" spread="64.72"/>
                    <measurement group_id="O3" value="2185.039" spread="NA">Geometric coefficient of variation could not be calculated for a single participant.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ctrough of Abiraterone</title>
        <description>Blood samples were collected at indicated time points for PK analysis of abiraterone. PK parameters were calculated using standard non-compartmental analysis.</description>
        <time_frame>Day 1: Pre-dose, 30 minutes, 1, 3, 6 to 12, 24 hours post-dose on Weeks 1 and 3</time_frame>
        <population>PK Population. Only those participants with data available at the indicated time points were analyzed (indicated by n=X in category titles).</population>
        <group_list>
          <group group_id="O1">
            <title>GSK525762 60 mg+Abiraterone 1000 mg</title>
            <description>Participants received once daily oral dose of GSK525762 60 milligram (mg) in combination with abiraterone 1000 mg up to maximum of 21.3 months. Participants received prednisone 5 mg orally twice daily as per abiraterone label.</description>
          </group>
          <group group_id="O2">
            <title>GSK525762 60 mg Alternate+Abiraterone 1000 mg</title>
            <description>Participants received an alternate dosing schedule- once daily GSK525762 60 mg + abiraterone 1000 mg tablets via the oral route for 2 weeks followed by 1 week off-treatment up to maximum of 21.3 months. Participants received prednisone 5 mg orally twice daily as per abiraterone label.</description>
          </group>
          <group group_id="O3">
            <title>GSK525762 40 mg+Abiraterone 1000 mg</title>
            <description>Participants received once daily oral dose of GSK525762 40 mg in combination with abiraterone 1000 mg up to maximum of 21.3 months. Participants received prednisone 5 mg orally twice daily as per abiraterone label.</description>
          </group>
        </group_list>
        <measure>
          <title>Ctrough of Abiraterone</title>
          <description>Blood samples were collected at indicated time points for PK analysis of abiraterone. PK parameters were calculated using standard non-compartmental analysis.</description>
          <population>PK Population. Only those participants with data available at the indicated time points were analyzed (indicated by n=X in category titles).</population>
          <units>Nanogram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1 Day 1, n=9,2,3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.603" spread="93.00"/>
                    <measurement group_id="O2" value="4.636" spread="1802.64"/>
                    <measurement group_id="O3" value="11.263" spread="86.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3 Day 1, n=2,4,1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.114" spread="9.84"/>
                    <measurement group_id="O2" value="7.697" spread="69.99"/>
                    <measurement group_id="O3" value="21.800" spread="NA">Geometric coefficient of variation could not be calculated for a single participant.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cmax of Enzalutamide</title>
        <description>Blood samples were collected at indicated time points for PK analysis of enzalutamide. PK parameters were calculated using standard non-compartmental analysis.</description>
        <time_frame>Day 1: Pre-dose on Weeks 1, 3, 5, 9, 17 and 25</time_frame>
        <population>PK Population. Cmax could not be derived as only pre-dose samples were collected.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK525762 80 mg+Enzalutamide 160 mg</title>
            <description>Participants received once daily oral dose of GSK525762 80 mg in combination with enzalutamide 160 mg up to maximum of 21.3 months.</description>
          </group>
          <group group_id="O2">
            <title>GSK525762 60 mg+Enzalutamide 160 mg</title>
            <description>Participants received once daily oral dose of GSK525762 60 mg in combination with enzalutamide 160 mg up to maximum of 21.3 months.</description>
          </group>
          <group group_id="O3">
            <title>GSK525762 60 mg Alternate+Enzalutamide 160 mg</title>
            <description>Participants received an alternate dosing schedule- once daily GSK525762 60 mg + enzalutamide 160 mg tablets via the oral route for 2 weeks followed by 1 week off-treatment up to maximum of 21.3 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax of Enzalutamide</title>
          <description>Blood samples were collected at indicated time points for PK analysis of enzalutamide. PK parameters were calculated using standard non-compartmental analysis.</description>
          <population>PK Population. Cmax could not be derived as only pre-dose samples were collected.</population>
          <units>Microgram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">Cmax could not be derived as only pre-dose samples were collected.</measurement>
                    <measurement group_id="O2" value="NA" spread="NA">Cmax could not be derived as only pre-dose samples were collected.</measurement>
                    <measurement group_id="O3" value="NA" spread="NA">Cmax could not be derived as only pre-dose samples were collected.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tmax of Enzalutamide</title>
        <description>Blood samples were collected at indicated time points for PK analysis of enzalutamide. PK parameters were calculated using standard non-compartmental analysis.</description>
        <time_frame>Day 1: Pre-dose on Weeks 1, 3, 5, 9, 17 and 25</time_frame>
        <population>PK Population. Tmax could not be derived as only pre-dose samples were collected.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK525762 80 mg+Enzalutamide 160 mg</title>
            <description>Participants received once daily oral dose of GSK525762 80 mg in combination with enzalutamide 160 mg up to maximum of 21.3 months.</description>
          </group>
          <group group_id="O2">
            <title>GSK525762 60 mg+Enzalutamide 160 mg</title>
            <description>Participants received once daily oral dose of GSK525762 60 mg in combination with enzalutamide 160 mg up to maximum of 21.3 months.</description>
          </group>
          <group group_id="O3">
            <title>GSK525762 60 mg Alternate+Enzalutamide 160 mg</title>
            <description>Participants received an alternate dosing schedule- once daily GSK525762 60 mg + enzalutamide 160 mg tablets via the oral route for 2 weeks followed by 1 week off-treatment up to maximum of 21.3 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax of Enzalutamide</title>
          <description>Blood samples were collected at indicated time points for PK analysis of enzalutamide. PK parameters were calculated using standard non-compartmental analysis.</description>
          <population>PK Population. Tmax could not be derived as only pre-dose samples were collected.</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">Tmax could not be derived as only pre-dose samples were collected.</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">Tmax could not be derived as only pre-dose samples were collected.</measurement>
                    <measurement group_id="O3" value="NA" lower_limit="NA" upper_limit="NA">Tmax could not be derived as only pre-dose samples were collected.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC(0-tau) of Enzalutamide</title>
        <description>Blood samples were collected at indicated time points for PK analysis of enzalutamide. PK parameters were calculated using standard non-compartmental analysis.</description>
        <time_frame>Day 1: Pre-dose on Weeks 1, 3, 5, 9, 17 and 25</time_frame>
        <population>PK Population. AUC(0-tau) could not be derived as only pre-dose samples were collected.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK525762 80 mg+Enzalutamide 160 mg</title>
            <description>Participants received once daily oral dose of GSK525762 80 mg in combination with enzalutamide 160 mg up to maximum of 21.3 months.</description>
          </group>
          <group group_id="O2">
            <title>GSK525762 60 mg+Enzalutamide 160 mg</title>
            <description>Participants received once daily oral dose of GSK525762 60 mg in combination with enzalutamide 160 mg up to maximum of 21.3 months.</description>
          </group>
          <group group_id="O3">
            <title>GSK525762 60 mg Alternate+Enzalutamide 160 mg</title>
            <description>Participants received an alternate dosing schedule- once daily GSK525762 60 mg + enzalutamide 160 mg tablets via the oral route for 2 weeks followed by 1 week off-treatment up to maximum of 21.3 months.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC(0-tau) of Enzalutamide</title>
          <description>Blood samples were collected at indicated time points for PK analysis of enzalutamide. PK parameters were calculated using standard non-compartmental analysis.</description>
          <population>PK Population. AUC(0-tau) could not be derived as only pre-dose samples were collected.</population>
          <units>Hours*microgram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">AUC(0-tau) could not be derived as only pre-dose samples were collected</measurement>
                    <measurement group_id="O2" value="NA" spread="NA">AUC(0-tau) could not be derived as only pre-dose samples were collected</measurement>
                    <measurement group_id="O3" value="NA" spread="NA">AUC(0-tau) could not be derived as only pre-dose samples were collected</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ctrough of Enzalutamide</title>
        <description>Blood samples were collected at indicated time points for PK analysis of enzalutamide. PK parameters were calculated using standard non-compartmental analysis.</description>
        <time_frame>Day 1: Pre-dose on Weeks 1, 3, 5, 9, 17 and 25</time_frame>
        <population>PK Population. Only those participants with data available at the indicated time points were analyzed (indicated by n=X in category titles).</population>
        <group_list>
          <group group_id="O1">
            <title>GSK525762 80 mg+Enzalutamide 160 mg</title>
            <description>Participants received once daily oral dose of GSK525762 80 mg in combination with enzalutamide 160 mg up to maximum of 21.3 months.</description>
          </group>
          <group group_id="O2">
            <title>GSK525762 60 mg+Enzalutamide 160 mg</title>
            <description>Participants received once daily oral dose of GSK525762 60 mg in combination with enzalutamide 160 mg up to maximum of 21.3 months.</description>
          </group>
          <group group_id="O3">
            <title>GSK525762 60 mg Alternate+Enzalutamide 160 mg</title>
            <description>Participants received an alternate dosing schedule- once daily GSK525762 60 mg + enzalutamide 160 mg tablets via the oral route for 2 weeks followed by 1 week off-treatment up to maximum of 21.3 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Ctrough of Enzalutamide</title>
          <description>Blood samples were collected at indicated time points for PK analysis of enzalutamide. PK parameters were calculated using standard non-compartmental analysis.</description>
          <population>PK Population. Only those participants with data available at the indicated time points were analyzed (indicated by n=X in category titles).</population>
          <units>Microgram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1 Day 1, Pre-dose, n=9,20,18</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.066" spread="21.74"/>
                    <measurement group_id="O2" value="13.313" spread="21.70"/>
                    <measurement group_id="O3" value="14.546" spread="30.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3 Day 1, Pre-dose, n=9,19,13</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.385" spread="23.30"/>
                    <measurement group_id="O2" value="10.902" spread="24.96"/>
                    <measurement group_id="O3" value="11.497" spread="27.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5 Day 1, Pre-dose, n=10,15,18</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.026" spread="21.80"/>
                    <measurement group_id="O2" value="9.814" spread="44.21"/>
                    <measurement group_id="O3" value="12.561" spread="31.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 9 Day 1, Pre-dose, n=6,6,13</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.021" spread="27.01"/>
                    <measurement group_id="O2" value="8.064" spread="85.90"/>
                    <measurement group_id="O3" value="12.056" spread="30.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 17 Day 1, Pre-dose, n=4,2,4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.621" spread="22.86"/>
                    <measurement group_id="O2" value="12.568" spread="10.14"/>
                    <measurement group_id="O3" value="10.267" spread="58.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 25 Day 1, Pre-dose, n=2,2,2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.103" spread="8.13"/>
                    <measurement group_id="O2" value="13.069" spread="9.75"/>
                    <measurement group_id="O3" value="13.791" spread="5.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Disease Control Rate at Week 24</title>
        <description>Disease control rate (DCR) is defined as the percentage of participants with &gt;=1 post-Baseline disease assessment who showed either a confirmed complete response (CR), partial response (PR) or stable disease (SD) observed at &gt;=24 weeks per prostate cancer working group 3 (PCWG3)-modified Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1; where CR: disappearance of all target lesions. Any pathological lymph nodes must be &lt;10 millimeter in the short axis; PR: At least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the Baseline sum of the diameters; SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive diseases. Confidence interval (CI) was computed using exact two sided 95% CI.</description>
        <time_frame>Week 24</time_frame>
        <population>Modified All Treated Population. Only those participants with data available at the indicated time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK525762 60 mg+Abiraterone 1000 mg</title>
            <description>Participants received once daily oral dose of GSK525762 60 milligram (mg) in combination with abiraterone 1000 mg up to maximum of 21.3 months. Participants received prednisone 5 mg orally twice daily as per abiraterone label.</description>
          </group>
          <group group_id="O2">
            <title>GSK525762 60 mg Alternate+Abiraterone 1000 mg</title>
            <description>Participants received an alternate dosing schedule- once daily GSK525762 60 mg + abiraterone 1000 mg tablets via the oral route for 2 weeks followed by 1 week off-treatment up to maximum of 21.3 months. Participants received prednisone 5 mg orally twice daily as per abiraterone label.</description>
          </group>
          <group group_id="O3">
            <title>GSK525762 40 mg+Abiraterone 1000 mg</title>
            <description>Participants received once daily oral dose of GSK525762 40 mg in combination with abiraterone 1000 mg up to maximum of 21.3 months. Participants received prednisone 5 mg orally twice daily as per abiraterone label.</description>
          </group>
          <group group_id="O4">
            <title>GSK525762 80 mg+Enzalutamide 160 mg</title>
            <description>Participants received once daily oral dose of GSK525762 80 mg in combination with enzalutamide 160 mg up to maximum of 21.3 months.</description>
          </group>
          <group group_id="O5">
            <title>GSK525762 60 mg+Enzalutamide 160 mg</title>
            <description>Participants received once daily oral dose of GSK525762 60 mg in combination with enzalutamide 160 mg up to maximum of 21.3 months.</description>
          </group>
          <group group_id="O6">
            <title>GSK525762 60 mg Alternate+Enzalutamide 160 mg</title>
            <description>Participants received an alternate dosing schedule- once daily GSK525762 60 mg + enzalutamide 160 mg tablets via the oral route for 2 weeks followed by 1 week off-treatment up to maximum of 21.3 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Disease Control Rate at Week 24</title>
          <description>Disease control rate (DCR) is defined as the percentage of participants with &gt;=1 post-Baseline disease assessment who showed either a confirmed complete response (CR), partial response (PR) or stable disease (SD) observed at &gt;=24 weeks per prostate cancer working group 3 (PCWG3)-modified Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1; where CR: disappearance of all target lesions. Any pathological lymph nodes must be &lt;10 millimeter in the short axis; PR: At least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the Baseline sum of the diameters; SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive diseases. Confidence interval (CI) was computed using exact two sided 95% CI.</description>
          <population>Modified All Treated Population. Only those participants with data available at the indicated time points were analyzed.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="19"/>
                <count group_id="O6" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0.0" upper_limit="33.6"/>
                    <measurement group_id="O2" value="40" lower_limit="5.3" upper_limit="85.3"/>
                    <measurement group_id="O3" value="50" lower_limit="6.8" upper_limit="93.2"/>
                    <measurement group_id="O4" value="40" lower_limit="12.2" upper_limit="73.8"/>
                    <measurement group_id="O5" value="11" lower_limit="1.3" upper_limit="33.1"/>
                    <measurement group_id="O6" value="29" lower_limit="11.3" upper_limit="52.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Composite Response Rate</title>
        <description>Composite response rate was defined as the percentage of participants with one of the following: a) Response based on PCWG3-modified RECIST version 1.1, b) PSA decrease of &gt;=50% from Baseline at Week 12 and thereafter, or c) Circulating Tumor-cell Count Conversion from unfavorable (&gt;=5/7.5 milliliter [mL]) at Baseline to favorable (&lt;5/7.5 mL) confirmed by a second assessment at least 4 weeks later. If a participant met at least one of the above requirements, then that participant was considered a composite responder. CI was computed using exact two sided 95% CI.</description>
        <time_frame>Up to 21.3 months</time_frame>
        <population>Modified All Treated Population.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK525762 60 mg+Abiraterone 1000 mg</title>
            <description>Participants received once daily oral dose of GSK525762 60 milligram (mg) in combination with abiraterone 1000 mg up to maximum of 21.3 months. Participants received prednisone 5 mg orally twice daily as per abiraterone label.</description>
          </group>
          <group group_id="O2">
            <title>GSK525762 60 mg Alternate+Abiraterone 1000 mg</title>
            <description>Participants received an alternate dosing schedule- once daily GSK525762 60 mg + abiraterone 1000 mg tablets via the oral route for 2 weeks followed by 1 week off-treatment up to maximum of 21.3 months. Participants received prednisone 5 mg orally twice daily as per abiraterone label.</description>
          </group>
          <group group_id="O3">
            <title>GSK525762 40 mg+Abiraterone 1000 mg</title>
            <description>Participants received once daily oral dose of GSK525762 40 mg in combination with abiraterone 1000 mg up to maximum of 21.3 months. Participants received prednisone 5 mg orally twice daily as per abiraterone label.</description>
          </group>
          <group group_id="O4">
            <title>GSK525762 80 mg+Enzalutamide 160 mg</title>
            <description>Participants received once daily oral dose of GSK525762 80 mg in combination with enzalutamide 160 mg up to maximum of 21.3 months.</description>
          </group>
          <group group_id="O5">
            <title>GSK525762 60 mg+Enzalutamide 160 mg</title>
            <description>Participants received once daily oral dose of GSK525762 60 mg in combination with enzalutamide 160 mg up to maximum of 21.3 months.</description>
          </group>
          <group group_id="O6">
            <title>GSK525762 60 mg Alternate+Enzalutamide 160 mg</title>
            <description>Participants received an alternate dosing schedule- once daily GSK525762 60 mg + enzalutamide 160 mg tablets via the oral route for 2 weeks followed by 1 week off-treatment up to maximum of 21.3 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Composite Response Rate</title>
          <description>Composite response rate was defined as the percentage of participants with one of the following: a) Response based on PCWG3-modified RECIST version 1.1, b) PSA decrease of &gt;=50% from Baseline at Week 12 and thereafter, or c) Circulating Tumor-cell Count Conversion from unfavorable (&gt;=5/7.5 milliliter [mL]) at Baseline to favorable (&lt;5/7.5 mL) confirmed by a second assessment at least 4 weeks later. If a participant met at least one of the above requirements, then that participant was considered a composite responder. CI was computed using exact two sided 95% CI.</description>
          <population>Modified All Treated Population.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="22"/>
                <count group_id="O6" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0.0" upper_limit="30.8"/>
                    <measurement group_id="O2" value="0" lower_limit="0.0" upper_limit="45.9"/>
                    <measurement group_id="O3" value="0" lower_limit="0.0" upper_limit="60.2"/>
                    <measurement group_id="O4" value="10" lower_limit="0.3" upper_limit="44.5"/>
                    <measurement group_id="O5" value="5" lower_limit="0.1" upper_limit="22.8"/>
                    <measurement group_id="O6" value="0" lower_limit="0.0" upper_limit="16.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Objective Response Rate</title>
        <description>Objective response rate (ORR) is defined as the percentage of participants with a confirmed CR or PR at any time as per PCWG3-modified RECIST version 1.1; where CR: Disappearance of all target lesions. Any pathological lymph nodes must be &lt;10 millimeter (mm) in the short axis and PR: At least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the Baseline sum of the diameters.</description>
        <time_frame>Up to 21.3 months</time_frame>
        <population>Modified All Treated Population. Only those participants with data available at the indicated time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK525762 60 mg+Abiraterone 1000 mg</title>
            <description>Participants received once daily oral dose of GSK525762 60 milligram (mg) in combination with abiraterone 1000 mg up to maximum of 21.3 months. Participants received prednisone 5 mg orally twice daily as per abiraterone label.</description>
          </group>
          <group group_id="O2">
            <title>GSK525762 60 mg Alternate+Abiraterone 1000 mg</title>
            <description>Participants received an alternate dosing schedule- once daily GSK525762 60 mg + abiraterone 1000 mg tablets via the oral route for 2 weeks followed by 1 week off-treatment up to maximum of 21.3 months. Participants received prednisone 5 mg orally twice daily as per abiraterone label.</description>
          </group>
          <group group_id="O3">
            <title>GSK525762 40 mg+Abiraterone 1000 mg</title>
            <description>Participants received once daily oral dose of GSK525762 40 mg in combination with abiraterone 1000 mg up to maximum of 21.3 months. Participants received prednisone 5 mg orally twice daily as per abiraterone label.</description>
          </group>
          <group group_id="O4">
            <title>GSK525762 80 mg+Enzalutamide 160 mg</title>
            <description>Participants received once daily oral dose of GSK525762 80 mg in combination with enzalutamide 160 mg up to maximum of 21.3 months.</description>
          </group>
          <group group_id="O5">
            <title>GSK525762 60 mg+Enzalutamide 160 mg</title>
            <description>Participants received once daily oral dose of GSK525762 60 mg in combination with enzalutamide 160 mg up to maximum of 21.3 months.</description>
          </group>
          <group group_id="O6">
            <title>GSK525762 60 mg Alternate+Enzalutamide 160 mg</title>
            <description>Participants received an alternate dosing schedule- once daily GSK525762 60 mg + enzalutamide 160 mg tablets via the oral route for 2 weeks followed by 1 week off-treatment up to maximum of 21.3 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Objective Response Rate</title>
          <description>Objective response rate (ORR) is defined as the percentage of participants with a confirmed CR or PR at any time as per PCWG3-modified RECIST version 1.1; where CR: Disappearance of all target lesions. Any pathological lymph nodes must be &lt;10 millimeter (mm) in the short axis and PR: At least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the Baseline sum of the diameters.</description>
          <population>Modified All Treated Population. Only those participants with data available at the indicated time points were analyzed.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="19"/>
                <count group_id="O6" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Circulating Tumor Cells (CTC) Response Rate</title>
        <description>CTC response rate is defined as the percentage of participants with a CTC conversion to &lt;5/7.5 mL blood at nadir (confirmed by a second consecutive value obtained four or more weeks later) for participants with unfavourable CTC (&gt;=5/7.5 mL) at Baseline. CI was computed using exact two sided 95% CI.</description>
        <time_frame>Up to 21.3 months</time_frame>
        <population>Modified All Treated Population. Only those participants with data available at the indicated time points were analyzed. For GSK525762 40 mg+Abiraterone 1000 mg arm, there were no unfavorable values at Baseline, hence CTC response rate (change from unfavorable to favorable) could not be derived for this arm.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK525762 60 mg+Abiraterone 1000 mg</title>
            <description>Participants received once daily oral dose of GSK525762 60 milligram (mg) in combination with abiraterone 1000 mg up to maximum of 21.3 months. Participants received prednisone 5 mg orally twice daily as per abiraterone label.</description>
          </group>
          <group group_id="O2">
            <title>GSK525762 60 mg Alternate+Abiraterone 1000 mg</title>
            <description>Participants received an alternate dosing schedule- once daily GSK525762 60 mg + abiraterone 1000 mg tablets via the oral route for 2 weeks followed by 1 week off-treatment up to maximum of 21.3 months. Participants received prednisone 5 mg orally twice daily as per abiraterone label.</description>
          </group>
          <group group_id="O3">
            <title>GSK525762 40 mg+Abiraterone 1000 mg</title>
            <description>Participants received once daily oral dose of GSK525762 40 mg in combination with abiraterone 1000 mg up to maximum of 21.3 months. Participants received prednisone 5 mg orally twice daily as per abiraterone label.</description>
          </group>
          <group group_id="O4">
            <title>GSK525762 80 mg+Enzalutamide 160 mg</title>
            <description>Participants received once daily oral dose of GSK525762 80 mg in combination with enzalutamide 160 mg up to maximum of 21.3 months.</description>
          </group>
          <group group_id="O5">
            <title>GSK525762 60 mg+Enzalutamide 160 mg</title>
            <description>Participants received once daily oral dose of GSK525762 60 mg in combination with enzalutamide 160 mg up to maximum of 21.3 months.</description>
          </group>
          <group group_id="O6">
            <title>GSK525762 60 mg Alternate+Enzalutamide 160 mg</title>
            <description>Participants received an alternate dosing schedule- once daily GSK525762 60 mg + enzalutamide 160 mg tablets via the oral route for 2 weeks followed by 1 week off-treatment up to maximum of 21.3 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Circulating Tumor Cells (CTC) Response Rate</title>
          <description>CTC response rate is defined as the percentage of participants with a CTC conversion to &lt;5/7.5 mL blood at nadir (confirmed by a second consecutive value obtained four or more weeks later) for participants with unfavourable CTC (&gt;=5/7.5 mL) at Baseline. CI was computed using exact two sided 95% CI.</description>
          <population>Modified All Treated Population. Only those participants with data available at the indicated time points were analyzed. For GSK525762 40 mg+Abiraterone 1000 mg arm, there were no unfavorable values at Baseline, hence CTC response rate (change from unfavorable to favorable) could not be derived for this arm.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="12"/>
                <count group_id="O6" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0.0" upper_limit="41.0"/>
                    <measurement group_id="O2" value="0" lower_limit="0.0" upper_limit="70.8"/>
                    <measurement group_id="O4" value="33" lower_limit="0.8" upper_limit="90.6"/>
                    <measurement group_id="O5" value="8" lower_limit="0.2" upper_limit="38.5"/>
                    <measurement group_id="O6" value="0" lower_limit="0.0" upper_limit="28.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Prostate-specific Antigen (PSA) Response Rate at Week 4</title>
        <description>PSA Response Rate is defined as percentage of participants achieving &gt;=30% decrease from Baseline PSA after 4 weeks of study treatment. The CI was calculated using exact two sided 95% CI for the percentage of participants with Baseline PSA values who show &gt;=30% reduction in PSA at &gt;=4 weeks post-Baseline.</description>
        <time_frame>Week 4</time_frame>
        <population>Modified All Treated Population.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK525762 60 mg+Abiraterone 1000 mg</title>
            <description>Participants received once daily oral dose of GSK525762 60 milligram (mg) in combination with abiraterone 1000 mg up to maximum of 21.3 months. Participants received prednisone 5 mg orally twice daily as per abiraterone label.</description>
          </group>
          <group group_id="O2">
            <title>GSK525762 60 mg Alternate+Abiraterone 1000 mg</title>
            <description>Participants received an alternate dosing schedule- once daily GSK525762 60 mg + abiraterone 1000 mg tablets via the oral route for 2 weeks followed by 1 week off-treatment up to maximum of 21.3 months. Participants received prednisone 5 mg orally twice daily as per abiraterone label.</description>
          </group>
          <group group_id="O3">
            <title>GSK525762 40 mg+Abiraterone 1000 mg</title>
            <description>Participants received once daily oral dose of GSK525762 40 mg in combination with abiraterone 1000 mg up to maximum of 21.3 months. Participants received prednisone 5 mg orally twice daily as per abiraterone label.</description>
          </group>
          <group group_id="O4">
            <title>GSK525762 80 mg+Enzalutamide 160 mg</title>
            <description>Participants received once daily oral dose of GSK525762 80 mg in combination with enzalutamide 160 mg up to maximum of 21.3 months.</description>
          </group>
          <group group_id="O5">
            <title>GSK525762 60 mg+Enzalutamide 160 mg</title>
            <description>Participants received once daily oral dose of GSK525762 60 mg in combination with enzalutamide 160 mg up to maximum of 21.3 months.</description>
          </group>
          <group group_id="O6">
            <title>GSK525762 60 mg Alternate+Enzalutamide 160 mg</title>
            <description>Participants received an alternate dosing schedule- once daily GSK525762 60 mg + enzalutamide 160 mg tablets via the oral route for 2 weeks followed by 1 week off-treatment up to maximum of 21.3 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Prostate-specific Antigen (PSA) Response Rate at Week 4</title>
          <description>PSA Response Rate is defined as percentage of participants achieving &gt;=30% decrease from Baseline PSA after 4 weeks of study treatment. The CI was calculated using exact two sided 95% CI for the percentage of participants with Baseline PSA values who show &gt;=30% reduction in PSA at &gt;=4 weeks post-Baseline.</description>
          <population>Modified All Treated Population.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="22"/>
                <count group_id="O6" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0.0" upper_limit="30.8"/>
                    <measurement group_id="O2" value="17" lower_limit="0.4" upper_limit="64.1"/>
                    <measurement group_id="O3" value="0" lower_limit="0.0" upper_limit="60.2"/>
                    <measurement group_id="O4" value="0" lower_limit="0.0" upper_limit="30.8"/>
                    <measurement group_id="O5" value="0" lower_limit="0.0" upper_limit="17.6"/>
                    <measurement group_id="O6" value="0" lower_limit="0.0" upper_limit="16.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Disease Progression</title>
        <description>Time to disease progression is defined as the time from date of first dose of study treatment to date of disease progression defined as one or more of the following criteria: 1. Radiographic progression by PCWG3-modified RECIST version 1.1 for participants with measurable disease, 2. Bone progression on bone scan according to the PCGW3 criteria, 3. PSA progression according to the PCWG3 criteria accompanied by any one of the following: investigator-defined clinical progression or either of the above RECIST version 1.1 radiographic progression or bone progression.</description>
        <time_frame>Up to 21.3 months</time_frame>
        <population>Modified All Treated Population.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK525762 60 mg+Abiraterone 1000 mg</title>
            <description>Participants received once daily oral dose of GSK525762 60 milligram (mg) in combination with abiraterone 1000 mg up to maximum of 21.3 months. Participants received prednisone 5 mg orally twice daily as per abiraterone label.</description>
          </group>
          <group group_id="O2">
            <title>GSK525762 60 mg Alternate+Abiraterone 1000 mg</title>
            <description>Participants received an alternate dosing schedule- once daily GSK525762 60 mg + abiraterone 1000 mg tablets via the oral route for 2 weeks followed by 1 week off-treatment up to maximum of 21.3 months. Participants received prednisone 5 mg orally twice daily as per abiraterone label.</description>
          </group>
          <group group_id="O3">
            <title>GSK525762 40 mg+Abiraterone 1000 mg</title>
            <description>Participants received once daily oral dose of GSK525762 40 mg in combination with abiraterone 1000 mg up to maximum of 21.3 months. Participants received prednisone 5 mg orally twice daily as per abiraterone label.</description>
          </group>
          <group group_id="O4">
            <title>GSK525762 80 mg+Enzalutamide 160 mg</title>
            <description>Participants received once daily oral dose of GSK525762 80 mg in combination with enzalutamide 160 mg up to maximum of 21.3 months.</description>
          </group>
          <group group_id="O5">
            <title>GSK525762 60 mg+Enzalutamide 160 mg</title>
            <description>Participants received once daily oral dose of GSK525762 60 mg in combination with enzalutamide 160 mg up to maximum of 21.3 months.</description>
          </group>
          <group group_id="O6">
            <title>GSK525762 60 mg Alternate+Enzalutamide 160 mg</title>
            <description>Participants received an alternate dosing schedule- once daily GSK525762 60 mg + enzalutamide 160 mg tablets via the oral route for 2 weeks followed by 1 week off-treatment up to maximum of 21.3 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Disease Progression</title>
          <description>Time to disease progression is defined as the time from date of first dose of study treatment to date of disease progression defined as one or more of the following criteria: 1. Radiographic progression by PCWG3-modified RECIST version 1.1 for participants with measurable disease, 2. Bone progression on bone scan according to the PCGW3 criteria, 3. PSA progression according to the PCWG3 criteria accompanied by any one of the following: investigator-defined clinical progression or either of the above RECIST version 1.1 radiographic progression or bone progression.</description>
          <population>Modified All Treated Population.</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="22"/>
                <count group_id="O6" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.0" lower_limit="36.0" upper_limit="88.0"/>
                    <measurement group_id="O2" value="NA" lower_limit="86.0" upper_limit="NA">&lt;50% of participants experienced the event within the treatment arm. Hence, median and third-quartile could not be derived.</measurement>
                    <measurement group_id="O3" value="NA" lower_limit="36.0" upper_limit="NA">&lt;50% of participants experienced the event within the treatment arm. Hence, median and third-quartile could not be derived.</measurement>
                    <measurement group_id="O4" value="87.0" lower_limit="85.0" upper_limit="112.0"/>
                    <measurement group_id="O5" value="86.0" lower_limit="56.0" upper_limit="NA">&lt;75% of participants experienced the event within the treatment arm. Hence, third-quartile could not be derived.</measurement>
                    <measurement group_id="O6" value="84.0" lower_limit="52.0" upper_limit="330.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Radiographic Progression-free Survival (rPFS)</title>
        <description>rPFS is defined as the time from study treatment start until the first date of either disease progression or death due to any cause. The date of disease progression is defined as the earliest date of disease progression as assessed by the investigator using PCWG3-modified RECIST, version 1.1 or progression on bone scan. Progressive disease is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as a reference, the smallest sum of diameters recorded since the treatment started.</description>
        <time_frame>Up to 21.3 montths</time_frame>
        <population>Modified All Treated Population.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK525762 60 mg+Abiraterone 1000 mg</title>
            <description>Participants received once daily oral dose of GSK525762 60 milligram (mg) in combination with abiraterone 1000 mg up to maximum of 21.3 months. Participants received prednisone 5 mg orally twice daily as per abiraterone label.</description>
          </group>
          <group group_id="O2">
            <title>GSK525762 60 mg Alternate+Abiraterone 1000 mg</title>
            <description>Participants received an alternate dosing schedule- once daily GSK525762 60 mg + abiraterone 1000 mg tablets via the oral route for 2 weeks followed by 1 week off-treatment up to maximum of 21.3 months. Participants received prednisone 5 mg orally twice daily as per abiraterone label.</description>
          </group>
          <group group_id="O3">
            <title>GSK525762 40 mg+Abiraterone 1000 mg</title>
            <description>Participants received once daily oral dose of GSK525762 40 mg in combination with abiraterone 1000 mg up to maximum of 21.3 months. Participants received prednisone 5 mg orally twice daily as per abiraterone label.</description>
          </group>
          <group group_id="O4">
            <title>GSK525762 80 mg+Enzalutamide 160 mg</title>
            <description>Participants received once daily oral dose of GSK525762 80 mg in combination with enzalutamide 160 mg up to maximum of 21.3 months.</description>
          </group>
          <group group_id="O5">
            <title>GSK525762 60 mg+Enzalutamide 160 mg</title>
            <description>Participants received once daily oral dose of GSK525762 60 mg in combination with enzalutamide 160 mg up to maximum of 21.3 months.</description>
          </group>
          <group group_id="O6">
            <title>GSK525762 60 mg Alternate+Enzalutamide 160 mg</title>
            <description>Participants received an alternate dosing schedule- once daily GSK525762 60 mg + enzalutamide 160 mg tablets via the oral route for 2 weeks followed by 1 week off-treatment up to maximum of 21.3 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Radiographic Progression-free Survival (rPFS)</title>
          <description>rPFS is defined as the time from study treatment start until the first date of either disease progression or death due to any cause. The date of disease progression is defined as the earliest date of disease progression as assessed by the investigator using PCWG3-modified RECIST, version 1.1 or progression on bone scan. Progressive disease is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as a reference, the smallest sum of diameters recorded since the treatment started.</description>
          <population>Modified All Treated Population.</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="22"/>
                <count group_id="O6" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.0" lower_limit="29.5" upper_limit="165.0"/>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">&lt;25% of participants experienced the event within the treatment arm. Hence, median and inter-quartile range could not be derived.</measurement>
                    <measurement group_id="O3" value="NA" lower_limit="36.0" upper_limit="NA">&lt;50% of participants experienced the event within the treatment arm. Hence, median and third-quartile could not be derived.</measurement>
                    <measurement group_id="O4" value="416.0" lower_limit="165.0" upper_limit="421.0"/>
                    <measurement group_id="O5" value="141.0" lower_limit="56.0" upper_limit="220.0"/>
                    <measurement group_id="O6" value="330.0" lower_limit="52.0" upper_limit="333.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Worst-Case Post Baseline Eastern Cooperative Oncology Group (ECOG) Performance Status</title>
        <description>Performance status assessments were based on 6-point ECOG scale (from 0 to 5), where 0=fully active, able to carry on all pre-disease performance without restriction; 1=restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature (e.g., light house work, office work); 2=ambulatory and capable of all self-care but unable to carry out any work activities, up and about more than 50% of waking hours; 3=capable of only limited self-care, confined to bed or chair more than 50% of waking hours; 4=completely disabled, cannot carry on any self-care, totally confined to bed or chair; and 5=dead. Data for worst case post-Baseline is presented.</description>
        <time_frame>Up to 21.3 months</time_frame>
        <population>All Treated Population. Only those participants with data available at the indicated time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK525762 60 mg+Abiraterone 1000 mg</title>
            <description>Participants received once daily oral dose of GSK525762 60 milligram (mg) in combination with abiraterone 1000 mg up to maximum of 21.3 months. Participants received prednisone 5 mg orally twice daily as per abiraterone label.</description>
          </group>
          <group group_id="O2">
            <title>GSK525762 60 mg Alternate+Abiraterone 1000 mg</title>
            <description>Participants received an alternate dosing schedule- once daily GSK525762 60 mg + abiraterone 1000 mg tablets via the oral route for 2 weeks followed by 1 week off-treatment up to maximum of 21.3 months. Participants received prednisone 5 mg orally twice daily as per abiraterone label.</description>
          </group>
          <group group_id="O3">
            <title>GSK525762 40 mg+Abiraterone 1000 mg</title>
            <description>Participants received once daily oral dose of GSK525762 40 mg in combination with abiraterone 1000 mg up to maximum of 21.3 months. Participants received prednisone 5 mg orally twice daily as per abiraterone label.</description>
          </group>
          <group group_id="O4">
            <title>GSK525762 80 mg+Enzalutamide 160 mg</title>
            <description>Participants received once daily oral dose of GSK525762 80 mg in combination with enzalutamide 160 mg up to maximum of 21.3 months.</description>
          </group>
          <group group_id="O5">
            <title>GSK525762 60 mg+Enzalutamide 160 mg</title>
            <description>Participants received once daily oral dose of GSK525762 60 mg in combination with enzalutamide 160 mg up to maximum of 21.3 months.</description>
          </group>
          <group group_id="O6">
            <title>GSK525762 60 mg Alternate+Enzalutamide 160 mg</title>
            <description>Participants received an alternate dosing schedule- once daily GSK525762 60 mg + enzalutamide 160 mg tablets via the oral route for 2 weeks followed by 1 week off-treatment up to maximum of 21.3 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Worst-Case Post Baseline Eastern Cooperative Oncology Group (ECOG) Performance Status</title>
          <description>Performance status assessments were based on 6-point ECOG scale (from 0 to 5), where 0=fully active, able to carry on all pre-disease performance without restriction; 1=restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature (e.g., light house work, office work); 2=ambulatory and capable of all self-care but unable to carry out any work activities, up and about more than 50% of waking hours; 3=capable of only limited self-care, confined to bed or chair more than 50% of waking hours; 4=completely disabled, cannot carry on any self-care, totally confined to bed or chair; and 5=dead. Data for worst case post-Baseline is presented.</description>
          <population>All Treated Population. Only those participants with data available at the indicated time points were analyzed.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="21"/>
                <count group_id="O6" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="16"/>
                    <measurement group_id="O6" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4-5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC QLQ-C30): Global Health Status (GHS)</title>
        <description>EORTC QLQ-C30 includes 30-items with single and multi-item scales. These included 5 functional scales (physical functioning, role functioning, cognitive functioning, emotional functioning and social functioning, 3 symptom scales (fatigue, pain and nausea/vomiting), a GHS/ Quality-of-Life (QoL) scale, and six single items (constipation, diarrhea, insomnia, dyspnea, appetite loss and financial difficulties). Response options for GHS/QoL range from 1 to 4, where 1=not at all and 4=very much. Scores were averaged and transformed to a 0 to 100 scale, with higher scores representing a high QoL. Baseline is defined as the latest non-missing assessment time-point prior to the first study treatment dose. Change from Baseline was calculated as post-Baseline visit value minus Baseline value.</description>
        <time_frame>Baseline (up to Week 1 Day 1, pre-dose) and at Weeks 1, 2, 3, 4, 5, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, 61 on Day 1</time_frame>
        <population>Modified All Treated Population. Only those participants with data available at the indicated time points were analyzed (indicated by n=X in category titles).</population>
        <group_list>
          <group group_id="O1">
            <title>GSK525762 60 mg+Abiraterone 1000 mg</title>
            <description>Participants received once daily oral dose of GSK525762 60 milligram (mg) in combination with abiraterone 1000 mg up to maximum of 21.3 months. Participants received prednisone 5 mg orally twice daily as per abiraterone label.</description>
          </group>
          <group group_id="O2">
            <title>GSK525762 60 mg Alternate+Abiraterone 1000 mg</title>
            <description>Participants received an alternate dosing schedule- once daily GSK525762 60 mg + abiraterone 1000 mg tablets via the oral route for 2 weeks followed by 1 week off-treatment up to maximum of 21.3 months. Participants received prednisone 5 mg orally twice daily as per abiraterone label.</description>
          </group>
          <group group_id="O3">
            <title>GSK525762 40 mg+Abiraterone 1000 mg</title>
            <description>Participants received once daily oral dose of GSK525762 40 mg in combination with abiraterone 1000 mg up to maximum of 21.3 months. Participants received prednisone 5 mg orally twice daily as per abiraterone label.</description>
          </group>
          <group group_id="O4">
            <title>GSK525762 80 mg+Enzalutamide 160 mg</title>
            <description>Participants received once daily oral dose of GSK525762 80 mg in combination with enzalutamide 160 mg up to maximum of 21.3 months.</description>
          </group>
          <group group_id="O5">
            <title>GSK525762 60 mg+Enzalutamide 160 mg</title>
            <description>Participants received once daily oral dose of GSK525762 60 mg in combination with enzalutamide 160 mg up to maximum of 21.3 months.</description>
          </group>
          <group group_id="O6">
            <title>GSK525762 60 mg Alternate+Enzalutamide 160 mg</title>
            <description>Participants received an alternate dosing schedule- once daily GSK525762 60 mg + enzalutamide 160 mg tablets via the oral route for 2 weeks followed by 1 week off-treatment up to maximum of 21.3 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC QLQ-C30): Global Health Status (GHS)</title>
          <description>EORTC QLQ-C30 includes 30-items with single and multi-item scales. These included 5 functional scales (physical functioning, role functioning, cognitive functioning, emotional functioning and social functioning, 3 symptom scales (fatigue, pain and nausea/vomiting), a GHS/ Quality-of-Life (QoL) scale, and six single items (constipation, diarrhea, insomnia, dyspnea, appetite loss and financial difficulties). Response options for GHS/QoL range from 1 to 4, where 1=not at all and 4=very much. Scores were averaged and transformed to a 0 to 100 scale, with higher scores representing a high QoL. Baseline is defined as the latest non-missing assessment time-point prior to the first study treatment dose. Change from Baseline was calculated as post-Baseline visit value minus Baseline value.</description>
          <population>Modified All Treated Population. Only those participants with data available at the indicated time points were analyzed (indicated by n=X in category titles).</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="2"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1 Day 1,n=1,0,0,0,2,0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="2"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.3" spread="NA">Standard deviation could not be calculated for single participant.</measurement>
                    <measurement group_id="O5" value="4.2" spread="5.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 Day 1,n=6,1,2,4,4,8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="4"/>
                    <count group_id="O5" value="4"/>
                    <count group_id="O6" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.3" spread="12.91"/>
                    <measurement group_id="O2" value="16.7" spread="NA">Standard deviation could not be calculated for single participant.</measurement>
                    <measurement group_id="O3" value="-12.5" spread="29.46"/>
                    <measurement group_id="O4" value="-2.1" spread="4.17"/>
                    <measurement group_id="O5" value="0.0" spread="13.61"/>
                    <measurement group_id="O6" value="-1.0" spread="12.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3 Day 1,n=6,0,1,4,3,7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="4"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.3" spread="23.57"/>
                    <measurement group_id="O3" value="-16.7" spread="NA">Standard deviation could not be calculated for single participant.</measurement>
                    <measurement group_id="O4" value="-4.2" spread="8.33"/>
                    <measurement group_id="O5" value="2.8" spread="4.81"/>
                    <measurement group_id="O6" value="-1.2" spread="3.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 Day 1,n=6,1,2,3,6,10</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="3"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.3" spread="10.54"/>
                    <measurement group_id="O2" value="16.7" spread="NA">Standard deviation could not be calculated for single participant.</measurement>
                    <measurement group_id="O3" value="0.0" spread="11.79"/>
                    <measurement group_id="O4" value="5.6" spread="9.62"/>
                    <measurement group_id="O5" value="1.4" spread="9.74"/>
                    <measurement group_id="O6" value="2.5" spread="16.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5 Day 1,n=3,0,1,3,5,9</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="3"/>
                    <count group_id="O5" value="5"/>
                    <count group_id="O6" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.3" spread="14.43"/>
                    <measurement group_id="O3" value="8.3" spread="NA">Standard deviation could not be calculated for single participant.</measurement>
                    <measurement group_id="O4" value="-5.6" spread="9.62"/>
                    <measurement group_id="O5" value="0.0" spread="11.79"/>
                    <measurement group_id="O6" value="-0.0" spread="11.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 9 Day 1,n=2,0,1,2,3,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="2"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.5" spread="17.68"/>
                    <measurement group_id="O3" value="-8.3" spread="NA">Standard deviation could not be calculated for single participant.</measurement>
                    <measurement group_id="O4" value="-20.8" spread="5.89"/>
                    <measurement group_id="O5" value="-30.6" spread="12.73"/>
                    <measurement group_id="O6" value="-12.5" spread="10.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 13 Day 1,n=1,1,1,1,2,3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="1"/>
                    <count group_id="O5" value="2"/>
                    <count group_id="O6" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-25.0" spread="NA">Standard deviation could not be calculated for single participant.</measurement>
                    <measurement group_id="O2" value="8.3" spread="NA">Standard deviation could not be calculated for single participant.</measurement>
                    <measurement group_id="O3" value="0.0" spread="NA">Standard deviation could not be calculated for single participant.</measurement>
                    <measurement group_id="O4" value="0.0" spread="NA">Standard deviation could not be calculated for single participant.</measurement>
                    <measurement group_id="O5" value="-8.3" spread="11.79"/>
                    <measurement group_id="O6" value="0.0" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 17 Day 1,n=1,1,1,1,1,3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="1"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-25.0" spread="NA">Standard deviation could not be calculated for single participant.</measurement>
                    <measurement group_id="O2" value="-16.7" spread="NA">Standard deviation could not be calculated for single participant.</measurement>
                    <measurement group_id="O3" value="16.7" spread="NA">Standard deviation could not be calculated for single participant.</measurement>
                    <measurement group_id="O4" value="0.0" spread="NA">Standard deviation could not be calculated for single participant.</measurement>
                    <measurement group_id="O5" value="0.0" spread="NA">Standard deviation could not be calculated for single participant.</measurement>
                    <measurement group_id="O6" value="-11.1" spread="19.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 21 Day 1,n=0,0,1,1,0,2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="1"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="16.7" spread="NA">Standard deviation could not be calculated for single participant.</measurement>
                    <measurement group_id="O4" value="0.0" spread="NA">Standard deviation could not be calculated for single participant.</measurement>
                    <measurement group_id="O6" value="-4.2" spread="5.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 25 Day 1,n=0,0,1,0,0,1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="0.0" spread="NA">Standard deviation could not be calculated for single participant.</measurement>
                    <measurement group_id="O6" value="-8.3" spread="NA">Standard deviation could not be calculated for single participant.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 29 Day 1,n=0,0,0,0,0,2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O6" value="-8.3" spread="11.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 33 Day 1,n=0,0,1,0,1,2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="8.3" spread="NA">Standard deviation could not be calculated for single participant.</measurement>
                    <measurement group_id="O5" value="0.0" spread="NA">Standard deviation could not be calculated for single participant.</measurement>
                    <measurement group_id="O6" value="-8.3" spread="11.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 37 Day 1,n=0,0,1,0,0,3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="0.0" spread="NA">Standard deviation could not be calculated for single participant.</measurement>
                    <measurement group_id="O6" value="-2.8" spread="4.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 41 Day 1,n=0,0,1,0,0,0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="8.3" spread="NA">Standard deviation could not be calculated for single participant.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 45 Day 1,n=0,0,1,0,0,1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="-8.3" spread="NA">Standard deviation could not be calculated for single participant.</measurement>
                    <measurement group_id="O6" value="0.0" spread="NA">Standard deviation could not be calculated for single participant.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 49 Day 1,n=0,0,1,0,0,2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="16.7" spread="NA">Standard deviation could not be calculated for single participant.</measurement>
                    <measurement group_id="O6" value="-8.3" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 61 Day 1,n=0,0,1,0,0,1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="16.7" spread="NA">Standard deviation could not be calculated for single participant.</measurement>
                    <measurement group_id="O6" value="-16.7" spread="NA">Standard deviation could not be calculated for single participant.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Brief Pain Inventory - Short Form (BPI-SF): Pain Intensity- Pain at Worst in Last 24 Hours</title>
        <description>BPI-SF is 9-item self-administered questionnaire. Pain intensity score was calculated from the four items (items 3, 4, 5 and 6) for worst pain, least pain, average pain and current pain. Worst pain in last 24 hours was rated from 0 (no pain) to 10 (pain as bad as you can imagine). Baseline is defined as the latest non-missing assessment time-point prior to the first study treatment dose (latest up to Week 1 Day 1). Change from Baseline was calculated as post-Baseline visit value minus Baseline value.</description>
        <time_frame>Baseline (up to pre-dose on Week 1 Day 1) and at Weeks 2, 3, 4, 5, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, 61, 73, 85, 97 on Day 1</time_frame>
        <population>Modified All Treated Population. Only those participants with data available at the indicated time points were analyzed (indicated by n=X in category titles).</population>
        <group_list>
          <group group_id="O1">
            <title>GSK525762 60 mg+Abiraterone 1000 mg</title>
            <description>Participants received once daily oral dose of GSK525762 60 milligram (mg) in combination with abiraterone 1000 mg up to maximum of 21.3 months. Participants received prednisone 5 mg orally twice daily as per abiraterone label.</description>
          </group>
          <group group_id="O2">
            <title>GSK525762 60 mg Alternate+Abiraterone 1000 mg</title>
            <description>Participants received an alternate dosing schedule- once daily GSK525762 60 mg + abiraterone 1000 mg tablets via the oral route for 2 weeks followed by 1 week off-treatment up to maximum of 21.3 months. Participants received prednisone 5 mg orally twice daily as per abiraterone label.</description>
          </group>
          <group group_id="O3">
            <title>GSK525762 40 mg+Abiraterone 1000 mg</title>
            <description>Participants received once daily oral dose of GSK525762 40 mg in combination with abiraterone 1000 mg up to maximum of 21.3 months. Participants received prednisone 5 mg orally twice daily as per abiraterone label.</description>
          </group>
          <group group_id="O4">
            <title>GSK525762 80 mg+Enzalutamide 160 mg</title>
            <description>Participants received once daily oral dose of GSK525762 80 mg in combination with enzalutamide 160 mg up to maximum of 21.3 months.</description>
          </group>
          <group group_id="O5">
            <title>GSK525762 60 mg+Enzalutamide 160 mg</title>
            <description>Participants received once daily oral dose of GSK525762 60 mg in combination with enzalutamide 160 mg up to maximum of 21.3 months.</description>
          </group>
          <group group_id="O6">
            <title>GSK525762 60 mg Alternate+Enzalutamide 160 mg</title>
            <description>Participants received an alternate dosing schedule- once daily GSK525762 60 mg + enzalutamide 160 mg tablets via the oral route for 2 weeks followed by 1 week off-treatment up to maximum of 21.3 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Brief Pain Inventory - Short Form (BPI-SF): Pain Intensity- Pain at Worst in Last 24 Hours</title>
          <description>BPI-SF is 9-item self-administered questionnaire. Pain intensity score was calculated from the four items (items 3, 4, 5 and 6) for worst pain, least pain, average pain and current pain. Worst pain in last 24 hours was rated from 0 (no pain) to 10 (pain as bad as you can imagine). Baseline is defined as the latest non-missing assessment time-point prior to the first study treatment dose (latest up to Week 1 Day 1). Change from Baseline was calculated as post-Baseline visit value minus Baseline value.</description>
          <population>Modified All Treated Population. Only those participants with data available at the indicated time points were analyzed (indicated by n=X in category titles).</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="19"/>
                <count group_id="O6" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2 Day 1,n=9,5,4,9,14,13</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="14"/>
                    <count group_id="O6" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="2.62"/>
                    <measurement group_id="O2" value="0.8" spread="2.86"/>
                    <measurement group_id="O3" value="-2.3" spread="1.71"/>
                    <measurement group_id="O4" value="0.0" spread="1.12"/>
                    <measurement group_id="O5" value="0.0" spread="2.91"/>
                    <measurement group_id="O6" value="0.2" spread="1.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3 Day 1,n=8,3,4,10,16,15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="16"/>
                    <count group_id="O6" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="1.77"/>
                    <measurement group_id="O2" value="-1.7" spread="1.53"/>
                    <measurement group_id="O3" value="-1.8" spread="1.89"/>
                    <measurement group_id="O4" value="-1.0" spread="2.05"/>
                    <measurement group_id="O5" value="0.3" spread="3.26"/>
                    <measurement group_id="O6" value="0.0" spread="1.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 Day 1,n=8,4,3,8,16,15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="16"/>
                    <count group_id="O6" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="1.92"/>
                    <measurement group_id="O2" value="0.5" spread="1.91"/>
                    <measurement group_id="O3" value="-1.3" spread="1.15"/>
                    <measurement group_id="O4" value="-0.8" spread="1.28"/>
                    <measurement group_id="O5" value="0.2" spread="2.81"/>
                    <measurement group_id="O6" value="0.4" spread="1.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5 Day 1,n=6,4,4,10,19,17</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="19"/>
                    <count group_id="O6" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" spread="3.06"/>
                    <measurement group_id="O2" value="-0.3" spread="1.26"/>
                    <measurement group_id="O3" value="-1.0" spread="0.82"/>
                    <measurement group_id="O4" value="-0.9" spread="2.13"/>
                    <measurement group_id="O5" value="0.7" spread="3.38"/>
                    <measurement group_id="O6" value="-0.2" spread="1.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 9 Day 1,n=3,4,3,8,10,13</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="10"/>
                    <count group_id="O6" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="1.53"/>
                    <measurement group_id="O2" value="1.3" spread="0.96"/>
                    <measurement group_id="O3" value="-0.3" spread="2.52"/>
                    <measurement group_id="O4" value="-0.5" spread="2.07"/>
                    <measurement group_id="O5" value="0.2" spread="2.49"/>
                    <measurement group_id="O6" value="-0.4" spread="2.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 13 Day 1,n=2,3,1,5,7,7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="7"/>
                    <count group_id="O6" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="0.71"/>
                    <measurement group_id="O2" value="2.0" spread="3.00"/>
                    <measurement group_id="O3" value="2.0" spread="NA">Standard deviation could not be calculated for single participant.</measurement>
                    <measurement group_id="O4" value="0.2" spread="1.92"/>
                    <measurement group_id="O5" value="-1.7" spread="2.21"/>
                    <measurement group_id="O6" value="-0.4" spread="2.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 17 Day 1,n=2,4,2,5,3,8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" spread="7.78"/>
                    <measurement group_id="O2" value="3.5" spread="4.36"/>
                    <measurement group_id="O3" value="-0.5" spread="4.95"/>
                    <measurement group_id="O4" value="-0.8" spread="3.11"/>
                    <measurement group_id="O5" value="-1.3" spread="1.15"/>
                    <measurement group_id="O6" value="-0.5" spread="2.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 21 Day 1,n=1,2,2,5,3,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" spread="NA">Standard deviation could not be calculated for single participant.</measurement>
                    <measurement group_id="O2" value="0.5" spread="0.71"/>
                    <measurement group_id="O3" value="-2.5" spread="0.71"/>
                    <measurement group_id="O4" value="-0.2" spread="2.49"/>
                    <measurement group_id="O5" value="-2.3" spread="4.04"/>
                    <measurement group_id="O6" value="1.0" spread="1.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 25 Day 1,n=0,0,1,2,3,4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="2"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="3.0" spread="NA">Standard deviation could not be calculated for single participant.</measurement>
                    <measurement group_id="O4" value="0.0" spread="0.00"/>
                    <measurement group_id="O5" value="-1.3" spread="5.69"/>
                    <measurement group_id="O6" value="-1.0" spread="1.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 29 Day 1,n=0,0,1,3,2,4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="3"/>
                    <count group_id="O5" value="2"/>
                    <count group_id="O6" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="-3.0" spread="NA">Standard deviation could not be calculated for single participant.</measurement>
                    <measurement group_id="O4" value="-0.7" spread="1.15"/>
                    <measurement group_id="O5" value="-3.5" spread="0.71"/>
                    <measurement group_id="O6" value="0.8" spread="4.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 33 Day 1,n=0,0,1,3,2,2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="3"/>
                    <count group_id="O5" value="2"/>
                    <count group_id="O6" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="1.0" spread="NA">Standard deviation could not be calculated for single participant.</measurement>
                    <measurement group_id="O4" value="0.7" spread="1.15"/>
                    <measurement group_id="O5" value="-1.5" spread="2.12"/>
                    <measurement group_id="O6" value="-1.0" spread="1.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 37 Day 1,n=0,0,1,3,0,4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="3"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="0.0" spread="NA">Standard deviation could not be calculated for single participant.</measurement>
                    <measurement group_id="O4" value="1.7" spread="2.08"/>
                    <measurement group_id="O6" value="0.0" spread="1.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 41 Day 1,n=0,0,1,3,1,1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="3"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="-1.0" spread="NA">Standard deviation could not be calculated for single participant.</measurement>
                    <measurement group_id="O4" value="1.3" spread="1.53"/>
                    <measurement group_id="O5" value="-3.0" spread="NA">Standard deviation could not be calculated for single participant.</measurement>
                    <measurement group_id="O6" value="-1.0" spread="NA">Standard deviation could not be calculated for single participant.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 45 Day 1,n=0,0,1,2,1,3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="2"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="1.0" spread="NA">Standard deviation could not be calculated for single participant.</measurement>
                    <measurement group_id="O4" value="2.5" spread="2.12"/>
                    <measurement group_id="O5" value="-1.0" spread="NA">Standard deviation could not be calculated for single participant.</measurement>
                    <measurement group_id="O6" value="1.7" spread="1.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 49 Day 1,n=0,0,1,3,1,3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="3"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="2.0" spread="NA">Standard deviation could not be calculated for single participant.</measurement>
                    <measurement group_id="O4" value="0.3" spread="1.53"/>
                    <measurement group_id="O5" value="-3.0" spread="NA">Standard deviation could not be calculated for single participant.</measurement>
                    <measurement group_id="O6" value="2.7" spread="2.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 61 Day 1,n=0,0,1,1,1,1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="1"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="-2.0" spread="NA">Standard deviation could not be calculated for single participant.</measurement>
                    <measurement group_id="O4" value="0.0" spread="NA">Standard deviation could not be calculated for single participant.</measurement>
                    <measurement group_id="O5" value="-3.0" spread="NA">Standard deviation could not be calculated for single participant.</measurement>
                    <measurement group_id="O6" value="3.0" spread="NA">Standard deviation could not be calculated for single participant.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 73 Day 1,n=0,0,0,1,1,0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="1"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O4" value="0.0" spread="NA">Standard deviation could not be calculated for single participant.</measurement>
                    <measurement group_id="O5" value="-2.0" spread="NA">Standard deviation could not be calculated for single participant.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 85 Day 1,n=0,0,0,1,1,0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="1"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O4" value="3.0" spread="NA">Standard deviation could not be calculated for single participant.</measurement>
                    <measurement group_id="O5" value="-3.0" spread="NA">Standard deviation could not be calculated for single participant.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 97 Day 1,n=0,0,0,0,1,0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="-3.0" spread="NA">Standard deviation could not be calculated for single participant.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All-cause mortality, non-SAEs and SAEs were collected up to 21.3 months</time_frame>
      <desc>All Treated Population consisted of all participants who received at least one dose of GSK525762 or abiraterone or enzalutamide. The results presented are based on the primary analysis approximately up to 3 years. Data collection is still on-going and additional results will be provided after study completion.</desc>
      <group_list>
        <group group_id="E1">
          <title>GSK525762 60 mg+Abiraterone 1000 mg</title>
          <description>Participants received once daily oral dose of GSK525762 60 milligram (mg) in combination with abiraterone 1000 mg up to maximum of 21.3 months. Participants received prednisone 5 mg orally twice daily as per abiraterone label.</description>
        </group>
        <group group_id="E2">
          <title>GSK525762 60 mg Alternate+Abiraterone 1000 mg</title>
          <description>Participants received an alternate dosing schedule- once daily GSK525762 60 mg + abiraterone 1000 mg tablets via the oral route for 2 weeks followed by 1 week off-treatment up to maximum of 21.3 months. Participants received prednisone 5 mg orally twice daily as per abiraterone label.</description>
        </group>
        <group group_id="E3">
          <title>GSK525762 40 mg+Abiraterone 1000 mg</title>
          <description>Participants received once daily oral dose of GSK525762 40 mg in combination with abiraterone 1000 mg up to maximum of 21.3 months. Participants received prednisone 5 mg orally twice daily as per abiraterone label.</description>
        </group>
        <group group_id="E4">
          <title>GSK525762 80 mg+Enzalutamide 160 mg</title>
          <description>Participants received once daily oral dose of GSK525762 80 mg in combination with enzalutamide 160 mg up to maximum of 21.3 months.</description>
        </group>
        <group group_id="E5">
          <title>GSK525762 60 mg+Enzalutamide 160 mg</title>
          <description>Participants received once daily oral dose of GSK525762 60 mg in combination with enzalutamide 160 mg up to maximum of 21.3 months.</description>
        </group>
        <group group_id="E6">
          <title>GSK525762 60 mg Alternate+Enzalutamide 160 mg</title>
          <description>Participants received an alternate dosing schedule- once daily GSK525762 60 mg + enzalutamide 160 mg tablets via the oral route for 2 weeks followed by 1 week off-treatment up to maximum of 21.3 months.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 23.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="10" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Disseminated intravascular coagulation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Myocarditis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Gastric haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Myelitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Clavicle fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Subdural haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Pathological fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Intraventricular haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Paraplegia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 23.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="22" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="21" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="10"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E5" events="8" subjects_affected="7" subjects_at_risk="22"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E5" events="14" subjects_affected="9" subjects_at_risk="22"/>
                <counts group_id="E6" events="6" subjects_affected="4" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="10"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" events="7" subjects_affected="6" subjects_at_risk="10"/>
                <counts group_id="E5" events="9" subjects_affected="8" subjects_at_risk="22"/>
                <counts group_id="E6" events="17" subjects_affected="11" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" events="5" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E5" events="10" subjects_affected="6" subjects_at_risk="22"/>
                <counts group_id="E6" events="10" subjects_affected="7" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E5" events="11" subjects_affected="6" subjects_at_risk="22"/>
                <counts group_id="E6" events="10" subjects_affected="7" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="10"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E5" events="18" subjects_affected="11" subjects_at_risk="22"/>
                <counts group_id="E6" events="9" subjects_affected="7" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E4" events="7" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E5" events="11" subjects_affected="8" subjects_at_risk="22"/>
                <counts group_id="E6" events="14" subjects_affected="11" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="10"/>
                <counts group_id="E2" events="5" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" events="17" subjects_affected="4" subjects_at_risk="10"/>
                <counts group_id="E5" events="5" subjects_affected="4" subjects_at_risk="22"/>
                <counts group_id="E6" events="8" subjects_affected="4" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Amylase increased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>International normalised ratio increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="7" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Troponin I increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="22"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="10"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E3" events="6" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E4" events="6" subjects_affected="4" subjects_at_risk="10"/>
                <counts group_id="E5" events="15" subjects_affected="9" subjects_at_risk="22"/>
                <counts group_id="E6" events="15" subjects_affected="13" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="10"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="5" subjects_affected="4" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" events="6" subjects_affected="4" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Hypertriglyceridaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="10"/>
                <counts group_id="E5" events="4" subjects_affected="3" subjects_at_risk="22"/>
                <counts group_id="E6" events="7" subjects_affected="6" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="22"/>
                <counts group_id="E6" events="5" subjects_affected="4" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="10"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E4" events="5" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E5" events="11" subjects_affected="7" subjects_at_risk="22"/>
                <counts group_id="E6" events="11" subjects_affected="10" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" events="5" subjects_affected="4" subjects_at_risk="10"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="22"/>
                <counts group_id="E6" events="4" subjects_affected="3" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" events="4" subjects_affected="3" subjects_at_risk="22"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E6" events="3" subjects_affected="2" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="10"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="22"/>
                <counts group_id="E6" events="5" subjects_affected="4" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E6" events="4" subjects_affected="2" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E5" events="4" subjects_affected="3" subjects_at_risk="22"/>
                <counts group_id="E6" events="3" subjects_affected="2" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" events="3" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

